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Emerging evidence suggests that the lower expression of SARS-CoV-2 
entry factor angiotensin-converting enzyme 2 (ACE2) and transmembrane 
serine protease 2 (TMPRSS2) in the nasal epithelium of children may contribute 
to lower incidence of COVID-19 in this age group compared to adults, yet no 
direct evidence is available for this hypothesis. In this study, we compared the 
transcript levels of ACE2 and TMPRSS2 in nasopharyngeal swabs (NPS) of 
children and their companion adults within COVID-19 exposed-families 
(n=207), to assess their association with infection status. Additionally, NPS 
specimens from COVID-19 positive and symptomatic children (n=24) and 
adults (n=10) were assessed for associations of ACE2 and TMPRSS2 
expression with patients’ clinical and laboratory outcomes.  
In the paired dataset, the expression of both genes was higher among 
adults (n=115) compared to children (n=92), but the expression was not 
significantly different between COVID-19 positive and negative patients of all 
ages or within the same age group. Within the same families, the expression of 
ACE2 and TMPRSS2 was higher in COVID-19 positive adults when compared 
to COVID-19 negative children (p=0.0002 and 0.0061, for ACE2 and 
TMPRSS2, respectively, by Wilcoxon Signed-Rank test, n=94), but the 
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expression of these genes was not significantly different between COVID-19 
positive adults and children or between COVID-19 negative adults and positive 
children. Consistently, the expression of both genes was positively associated 
with SARS-CoV-2 positivity in this subgroup only (OR: 1.146, 95%CI: 1.038-
1.284, p=0.0114 for ACE2 and OR: 1.123, 95%CI: 1.012-1.254, p=0.0334 for 
TMPRSS2). These findings suggest that children with lower expression of nasal 
ACE2 and TMPRSS2 are likely to remain COVID-19 negative despite being 
exposed to a COVID-19 positive family member.  
Using data from all specimens collected in this study and by grouping 
them as negative, asymptomatic and symptomatic for COVID-19, no significant 
association was found between the expression of ACE2 and TMPRSS2 genes 
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Chapter 1: Introduction   
In China, in December 2019, a string of pneumonia cases of undetermined 
etiology were reported [1]. Soon after, the Chinese Centre for Disease Control and 
Prevention discovered the presence of a new coronavirus in the throat swabs of 
affected patients. The novel virus resembled SARS-CoV, that caused severe acute 
respiratory syndrome with elevated fatality during 2002-2003 [2]. Afterward, the 
newly identified coronavirus was designated as Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2) and the disease is called coronavirus 
disease 2019 (COVID-19). Subsequently, a global pandemic was declared by 
World Health Organization in early March 2020. At the time of writing this review 
(March 08, 2021), the pandemic has affected many countries with more than 116.4 
million cases, and more than two million deaths have been associated with COVID-
19 were reported [3]. 
COVID-19 is principally a disease of the respiratory system, although the 
virus may also affect other organs. Clinical expression of SARS-CoV-2 infection is 
diverse, varying from asymptomatic to severe, life-threatening infection. Recent 
data suggests that up to 30 to 40% of the cases could be asymptomatic [4]. Among 
the symptomatic cases, most of the cases were mild, with flu-like symptoms being 
common among them, and only few experiencing severe disease with dyspnea, 
hypoxia, lung involvement, acute respiratory distress syndrome, shock, or multi-
organ failure, that could lead to death [5]. Other features such as myalgia, diarrhea, 
and loss of senses of smell or taste, are also common [6].  
The COVID-19 pandemic initiated urgent research on the transmission, 
pathogenesis, immune response, treatment and prevention of the virus transmission. 
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Currently there is a large gap in the understanding of the pathophysiology of the 
disease and the host response to SARS-CoV-2. The available knowledge in these 
areas so far is mostly derived from previously reported, similar coronaviruses such 
as MERS-CoV and SARS-CoV. The novel coronavirus, SARS-CoV-2, is one of 
the zoonotic viruses from beta-coronavirus family that has evolved to transmit 
between humans, and it has affected large numbers of people worldwide in a short 
period of time. SARS-CoV-2 has some important structural proteins that are 
necessary for viral replication, attachment and entry to host cells, which 
subsequently aid in the spread of the virus. The structural proteins include envelope, 
membrane, nucleocapsid, and spike proteins. Spike protein, which is the most 
important protein for virulence, protrudes from the viral surface, and is composed 
of dual functional subunits, S1 and S2. The S1 subunit functions in attachment to 
the target cell surface receptors, while the S2 subunit aids in merging the virus and 
the host cell membrane [7].  
Previously, it was reported that SARS-CoV gains access to human cells 
through the contact of its spike protein with angiotensin converting enzyme 2 
(ACE2) receptor [8]. Recent studies demonstrate that the novel SARS-CoV-2 
likewise interacts via the ACE2 receptor to gain entry into the human cells. ACE2 
is expressed in various body organs involving the lungs, kidney, bladder, ileum and 
heart. It is expressed at a much higher level in the respiratory tract than other tissues, 
and this could explain the common respiratory symptoms that are associated with 
COVID-19 infection [9].  
TMPRSS2 codes a protein that belongs to the serine protease family. 
TMPRSS2 contains a type II transmembrane domain, a scavenger receptor 
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cysteine-rich domain, a receptor class A domain and a protease domain. The protein 
remains membrane-bound with a noticeable part being embedded in the 
extracellular matrix. TMPRSS2 is involved in the proteolytic activation of influenza 
virus and coronaviruses including MERS-CoV and SARS-CoV [10]. SARS-CoV-
2 also uses the TMPRSS2 serine protease for S protein priming, and protease 
inhibitors have been shown to prevent SARS-CoV-2 entry into the host cells [11].  
SARS-CoV-2 can infect individuals of any age. Nevertheless, increased 
rates of SARS-CoV-2 infection were reported mainly among adults and elderly 
people. Also, the severe forms of SARS-CoV2 infection and rates of mortalities are 
much higher among elderly patients than in children, who experience mild to 
asymptomatic infection most of the time [12]. The factors contributing to the 
difference in the rates of infection among adults and pediatric patients is not clear 
yet. In a recent study, based on gene expression data from a non-COVID-19 cohort 
of asthma patients, it was hypothesized that the lower risk among children is due to 
differential expression of ACE2. The study shows that the expression levels of 
ACE2 in the nasal epithelium associates with age and proposed that the lower 
expression of ACE2 protein in the nasal epithelial cells of children may elucidate 
why children are less affected by COVID-19 [13]. Again, in cultured cells it was 
shown that cell lines that express TMPRSS2 are highly vulnerable to SARS-CoV-
2 infection [14]. Using a public gene expression dataset, it was also shown that the 
expression of nasal and bronchial SARS-CoV-2 target receptors, ACE2 and 
TMPRSS2, is lesser in children when compared to adults [15]. However, there is 
no direct evidence that correlates ACE2 and TMPRSS2 expression with lower rates 
of infections or the absence of symptoms or mild symptoms in children.  
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Worldwide, the total cases and deaths that are associated with COVID-19 
are still on rise. In the lack of an effective or specific treatment against the novel 
SARS-CoV-2 virus, early recognition and contact tracing, physical distancing 
measures and quarantine of positive cases have remained the principal measures to 
limit the community transmission of SARS-CoV-2. Understanding the 
pathogenicity of the virus and host factors in relation to the age of the patients is 
critical for potential therapeutic development, as well as the management of patients 
with COVID-19. 
Hypothesis: 
Nasal expression of ACE2 and TMPRSS2 determine differential SARS-
CoV-2 infection status in children and adults within the exposed families. 
Aim:  
 The aim is to analyze the transcript levels of nasal ACE2 and TMPRSS2 in 
nasopharyngeal (NP) swabs from children and adult members of exposed families 





Chapter 2: Literature Review  
2.1 Coronavirus disease 2019 
 In December 2019, a string of pneumonia cases was reported in Wuhan, 
China. Patients were presented with fever, dry cough, and shortness of breath and 
radiological evidence of bilateral lung infiltration [1]. The underlying etiology of 
this clinical phenotype was not known, until the Chinese Center for Disease Control 
and Prevention took throat swabs from affected individuals, and subsequently 
identified the presence of a novel coronavirus [2]. The newly identified coronavirus 
resembled severe acute respiratory syndrome coronavirus (SARS-CoV), which was 
associated with high morbidity and mortality back in 2002-2003 [16]. 
Consequently, the novel coronavirus 2019 was named severe acute respiratory 
syndrome coronavirus-2 (SARS-CoV-2) and the disease caused by SARS-CoV-2 
was named coronavirus disease 2019 (COVID-19). On March 11, 2020, a global 
pandemic was declared by the WHO and global preventive measures were 
implemented to prevent worldwide transmission of the disease. 
 
2.2 COVID-19 prevalence  
To date, SARS-CoV-2 affected a vast number of people worldwide. As of 
March 08, 2021, around 116.4 million confirmed cases of COVID-19 have been 
reported to WHO [17], including 2.6 million deaths globally (figure 1). Of these 
cases around 93 million recovered from infection. Currently the active infectious 
cases are approximately 21.9 million with only 0.4% with severe and critical form 
of infection and the rest with mild condition [3]. The available data to date shows 
that COVID-19 mortality rate is between 2-3%, which has evolved over the course 
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of the pandemic. In Qatar, according to the Ministry of Public Health, there were 
around 167 thousands of positive cases from the beginning of this pandemic to 
March 08, 2021, with only 10,855 active cases of COVID-19 (figure 2) [18]. SARS-
CoV-2 infects individuals of any age group, but many studies showed that children 
have lower rates of SARS-CoV-2 infection when compared to the adults. For 
instance, Chinese Center for Disease Control and Prevention reported that among 
44,672 confirmed cases of COVID-19, only 1% were children, with the rest being 
mainly adults and elderly patients [19]. While another study that was conducted in 
Korea revealed that only 4.8% of confirmed COVID-19 cases were children [20].  
 
 
Figure 1: COVID-19 confirmed cases data across regions, as of March 08, 2021. 
The data on the left of the figure shows cumulative COVID-19 positive cases across 
WHO regions. While the graph on the right shows COVID-19 weekly data in 





Figure 2: COVID-19 cases in Qatar, As of March 08, 2021. 
The Ministry of Public Health in Qatar updates COVID-19 status daily. In March 
8, 2021, there were 468 new cases of COVID-19, 298 recoveries and 1 death [18].    
 
2.3 Clinical presentation of COVID-19 
Clinical manifestations of COVID-19 are heterogenous. Infection with 
SARS-CoV-2 could result in asymptomatic infection: in a large cohort of COVID-
19 patients, around 30%-40% of positive cases were asymptomatic [4]. On the other 
hand, some patients experience symptomatic course of infection, that range from 
mild to moderate disease manifestations to severe and life-threatening forms of the 
disease that may lead to death. Symptomatic cases of COVID-19 experience flu-
like symptoms in most cases. Most common symptoms are fever, dry cough, 
dyspnea and fever and the involvement of lower respiratory tract, which could 
eventually lead to acute respiratory distress syndrome (ARDS) [21]. Other 
symptoms including, diarrhea, vomiting, generalized weakness, and headache were 
also reported among COVID-19 patients; this suggested that other organ systems 
are also affected by SARS-CoV-2 infection [22]. Various studies have been 
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conducted to determine the clinical presentations associated with COVID-19 (Table 
1). For instance, in a retrospective study that was conducted on 104 COVID-19 
patients from the Diamond Princess cruise ship, in Japan, the majority of COVID-
19 patient experienced either an asymptomatic (33/104) course of infection or a 
mild to moderate (43/104) respiratory infection, with fever, sore throat and dry 
cough, and these patients were eventually freed of infection and its associated 
symptoms within a few days. On the other hand, some infected individuals (28/104) 
experienced serious disease symptoms including, pulmonary edema, severe 
pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and 
subsequently multiple organ failure [23]. Also, in a retrospective study conducted 
on 41 COVID-19 hospitalized patients, other disease complications including acute 
cardiac injury, acute kidney injury, lymphopenia and secondary infections and 
thromboembolic events were identified [5]. Furthermore, in a recent systematic 
review it was shown that there is a high prevalence of smell and taste dysfunction 
among COVID-19 patients [6]. Several observational studies of laboratory findings 
in COVID-19 patients were assessed in a systematic review with a meta-analysis. 
The review included 4,663 patients, and the common abnormal laboratory findings 
among them were, elevated C-reactive protein (CRP, 73.6%), decreased albumin 
(62.9%), increased erythrocytes sedimentation rate (ESR, 61.2%), decreased 
eosinophils (58.4%), increased interleukin-6 (IL-6, 53.1%) lymphopenia (47.9%), 
and increased lactate dehydrogenase (LDH, 46.2%). Severe cases of the disease 
were found to be closely associated with increased CRP, LDH, and reduced 
lymphocyte count. Together these clinical phenotypes and laboratory findings could 
contribute to the diagnosis of COVID-19 [24].  
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SARS-CoV-2 infects people of different age groups with a varying degree 
of disease severity. Symptomatic severe cases of SARS-CoV-2 infection, that 
required hospitalization and intensive care were common among elderly patients 
especially those with comorbidities. The clinical characteristics of elderly COVID-
19 patients with young and middle-aged patients were compared in a retrospective 
study. It was found that elderly COVID-19 patients have higher pneumonia severity 
index (PSI) (grade VI and V), with multiple lobe involvement, and lower 
lymphocyte count. These data suggest that elderly people with SARS-CoV-2 
infection are more likely to develop severe forms of the disease, with high mortality 
rates. Furthermore, the higher mortality rates among elderly could be also related 
to variations in the lung anatomy, and muscle weakness, which eventually leads to 
changes in the normal function of the respiratory tract, such as reduced airway 
clearance and barrier defense, which render the host more susceptible to infection 
[12]. Poor prognosis from COVID-19 and higher morbidity and mortality rates have 
been associated with underlying metabolic conditions, including diabetes and 
cardiovascular diseases, at any age [25]. Also, it was found that patients with 
chronic obstructive pulmonary disease are at 4-fold higher risk of being infected 
with SARS-CoV-2 with severe disease outcome [26]. The association between 
body mass index (BMI) and clinical presentation of COVID-19 was also studied. It 
was found that among 124 patients, who required intensive care, 47.6% were obese 
with a BMI more than 30 kg/m2, and 28.2% were suffering from severe obesity 
with a BMI of more than 35 kg/m2. Disease severity is enhanced in patients with 




On the other hand, fewer cases of COVID-19 have been reported among 
children, which often presents with an asymptomatic course of infection or mild to 
moderate disease complications. In a study that was conducted in China in the initial 
stages of this pandemic, the clinical presentations of a cohort of 1099 patients were 
assessed: only 0.8% were children, and only one of them experienced a severe 
course of the disease [28]. Later on, a case series was reported by the Chinese Center 
for Disease control and prevention, that included 72,314 cases of which only 1% 
were children under the age of 10 years [19]. Furthermore, another study evaluated 
confirmed and suspected cases of COVID-19 among 1391 children, and they found 
that the incidence of SARS-CoV-2 infection increased to 12.3% [29]. In addition, 
similar to adults, children with COVID-19 experience a wide range of clinical 
manifestations of the disease, based on their general health, and the presence of 
other chronic diseases. Dong et al., evaluated the clinical presentation of COVID-
19 among 2135 pediatric patients, and they found that 4.4% of the cases were 
asymptomatic, 51% and 38.7% of the cases experienced mild to moderate disease 
symptoms, respectively [30]. Those with mild infection had fever, cough, runny 
nose, and some cases experienced gastrointestinal symptoms like diarrhea and 
vomiting. The moderate cases had pneumonia with frequent fever, productive 
cough, and their chest tomography revealed lung lesions [30]. Hence, pediatric 
symptoms are close to the ones observed among adults, but so far, no cases of 
anosmia have been reported. Furthermore, in a recent meta-analysis involving 1667 
pediatric patients, of which 19% where asymptomatic cases, only 3% of them were 
severe cases of COVID-19 and the rest experienced mild forms of the disease with 
fever and cough being the most common symptoms [31]. Furthermore, in another 
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meta-analysis, in which they included a total of 19 studies with 2855 children and 
adolescents with SARS-CoV-2 infection. They found that 79% of the cases 
presented with mild disease symptoms and 4% of the cases were critical. Also, they 
reported that around 47% experienced fever, 37% were presented with cough, 4% 
had diarrhea, 2% had nasal congestion, and 1% suffered from dyspnea. While none 
of the studies cases experienced abdominal discomfort [32]. The clinical 
presentation of COVID-19 is widely variable among children, adults, and elderly, 
especially those with underlying health condition, the reason behind this diversity 






















Table 1. Summary of COVID-19 clinical presentation per published reports 









cruise ship – 
Japan [23] 
104 31.7% 68.2% 
 
Mild to moderate symptoms (41.3 
%): fever, sore throat and dry 
cough. 
Severe infection (26.9 %): 
pulmonary edema, severe 
pneumonia, ARDS, septic shock 






NA 100% Acute cardiac injury (12 %), 
secondary infection (10 %) and 
acute kidney injury (7 %) and  
Systematic 
review [24] 
4663 - - Increased CRP (73.6%), ESR 
(61.2%), increased IL-6 (53.1%), 
decreased albumin (62.9%), 
decreased eosinophils (58.4%), 
lymphopenia (47.9%) and 










- 100% Higher PSI, multiple lobe 
involvement and 
lower lymphocyte count among 
elderly. 






years of age 





Fever (88.7%), cough (67.8%), 












Mild: non-pneumonia and mild 
pneumonia 
Severe: shortness of breath, lung 
infiltration 
Critical: respiratory failure, septic 
















Mild: fever, cough, runny nose, 
diarrhea and vomiting 
Moderate: pneumonia, fever, 
cough and lung lesions 
Systematic 
review [32] 
2855 17% 83% 
79% mild 
4% severe 
Fever (47%), cough (37%), 
diarrhea (4%), nasal congestion 





2.4 Causative agent and COVID-19 transmission  
  SARS-CoV-2 belongs to the family Coronaviridae, which are enveloped, 
positive-sense, single-stranded RNA viruses. Coronaviruses are divided into four 
genera, which include, , , , and  coronavirus [33]. The  and  coronaviruses 
are mainly found to infect mammals and cause pneumonia, acute lung injury, and 
acute respiratory distress syndrome and organ failure. SARS-CoV-2 belongs to the 
 coronavirus genus [34], along with previously reported SARS-CoV and Middle 
East Respiratory Syndrome (MERS-CoV) [35]. Coronaviruses in general, including 
SARS-CoV-2, have four essential structural proteins, that are necessary for viral 
attachment and penetration of the host, biosynthesis of viral proteins, maturation of 
new viral particles, and release of the virus. These structural proteins include spike 
glycoprotein (S), envelope glycoprotein (E), membrane glycoprotein (M), and 
nucleocapsid protein (N), in addition to other proteins that are necessary for the 
viral life cycle [7] (Figure 3). S glycoprotein is a transmembrane protein that 
protrude from the viral surface, which gives the virus a crown-like appearance, and 
it aids in the attachment and the fusion of the virus to the host cells. Viral S protein 
is cleaved to become functionally active by the host’s furin-like protease into S1 
and S2 subunit. The S1 subunit is found to function in the recognition and binding 
to host cell receptors and the S2 subunit aids in the subsequent fusion with the host 
membrane receptor [36]. Following the fusion of the virus with host membrane, N 
protein, which is found to be bound with RNA, aids in its entry to the host cells, 
and utilization of host’s cellular machinery for viral reproduction [37]. Furthermore, 
E glycoprotein is a component of viral envelope and it forms viroporins that are 
required for viral assembly and release [38]. M glycoprotein determines the shape 
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of the viral envelope, and it has the ability to bind to and stabilize N protein-RNA 
complex, and it further promotes viral assembly [39].  
 
 
Figure 3: Structural proteins of coronaviruses. 
All the structure proteins of SARS-CoV-2 are shown in the figure above and these 
proteins are essential for viral pathogenesis. Retrieved from [7]. 
 
The precise mechanism behind the disease initiation and subsequent 
transmission is not yet known. But due to the high similarities between SARS-CoV-
2 and other coronaviruses that are found in the bats, which is considered as a 
common reservoir for coronaviruses [40], and due to the previous gained 
knowledge about other coronaviruses that infected human, it is suggested that 
SARS-CoV-2 is a zoonotic virus that evolved to become capable of human-to-
human transmission. It has been reported that respiratory viruses in general are 
highly contagious during the symptomatic stages of the infection, while SARS-
CoV-2 is found to be infectious and contagious even in the incubation period of the 
virus when the patients are pre-symptomatic. SARS-CoV-2 can transmit and infect 
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people both directly and indirectly [41]. Direct transmission of the virus from one 
individual to another could occur through respiratory droplets that are generated 
when SARS-CoV-2 infected people sneeze, cough or even when they talk. In one 
experiment SARS-CoV-2 was viable in the aerosols after 3 hours, but there was a 
reduction in the TCID50 from 10^3.5 to 10^2.7 per liter of air [42]. SARS-CoV-2 
can also be transmitted indirectly via touching contaminated surfaces and objects. 
Knowing the mode of viral transmission could eventually help in determining 
effective ways to control and limit the spread of the virus. The virus typically 
accesses the human body, particularly to the lungs, through the mucosal membrane 
of the nose, mouth and eyes [43]. The nose is the most common route of 
internalizing aerosols through inhalation which makes it an important site for the 
initial stages of SARS-CoV-2 infection [44].    
 
2.5 Angiotensin-converting enzyme-2 (ACE2) and type 2 transmembrane 
serine protease TMPRSS2  
 ACE2 is a transmembrane protein that is encoded by a gene located on 
chromosome X [45]. ACE2 was first identified as a homolog of angiotensin-
converting enzyme, with an amino-terminal domain and carboxyl-terminal catalytic 
domain that contains the active zinc metalloprotein domain [46] [47]. ACE was 
found to play a role in the classic renin-angiotensin system to maintain blood 
pressure through catalyzing the conversion of angiotensin I to angiotensin II, the 
active peptide [48]. Functionally ACE2 is divided into two different groups: 
peptidase dependent and independent AEC2. Peptidase dependent ACE2 catalyzes 
the metabolism of angiotensin I and angiotensin II into angiotensin 1-9 and 
angiotensin 1-7, respectively. Angiotensin 1-7 has a protective opposing role to 
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angiotensin II, through binding to a G-coupled protein receptor, inducing 
vasorelaxation and diminishes pulmonary arterial hypertension and inflammation 
[49]. Peptidase independent ACE2 is mainly involved in the pathogenesis of 
coronavirus infection (described below), and the absorption of amino acids into gut 
epithelial cells [50]. ACE2 is found to be differentially expressed on various body 
organs. For instance, Zou et al., analyzed data from single-cell RNA sequencing of 
human systems and they reported that ACE2 is highly expressed on respiratory tract 
epithelial cells, particular on type 2 alveolar cells [51]. Also, ACE2 receptor is 
found on cardiac muscle cells, kidney tubule cells, urothelial cells and enterocytes 
[51].  
 ACE2 expression could be either detrimental or protective during COVID-
19 infection. Independent recent studies showed that SARS-CoV-2 requires ACE2 
receptor to successfully enter into the host cells and cause tissue damage [11] [52]. 
Similar to SARS-CoV, where it was found that increased expression of ACE2 
induced viral entry, and blocking the receptor protected against viral invasion and 
subsequent tissue damage [53] [54] [8]. On the other hand, the protective function 
of ACE has been also reported. ACE2 facilitates the degradation of angiotensin II, 
which exerts severe effects on the host, and these include myocardial dysfunction, 
endothelial dysfunction [55]. ACE2 also interferes with adaptive immune response, 
in such a way that enhance its response and increase the production of inflammatory 
cytokines, including IL-6, TNF-alpha and other cytokines developing a condition 
of cytokine storms that could negatively affect host tissue [56]. Furthermore, the 




 ACE2 can be either membrane bound or soluble in body fluids. Membrane-
bound ACE2 is essential for SARS-CoV-2 infection, since the virus needs to bind 
to the receptor active domain to successfully enter into host cells [54]. The 
expression of cell surface ACE2 is found to be higher in well-developed lung tissues 
when compared to immature ones, and a gene expression dataset revealed that 
ACE2 levels are higher among adults when compared to children and its expression 
increases with age [58] [15]. Angiotensin II is responsible for the formation of 
soluble ACE2, through increasing the production of transmembrane proteases such 
as TNF converting enzyme and ADAM-17. This occurs under normal conditions, 
infection, and acute lung injury [59]. The soluble ACE2 in serum samples from 
different age individuals was assessed and it was found that soluble ACE2 level 
increases with age and is associated with COVID-19 severity [60]. It was 
hypothesized that the high levels of soluble ACE2 is a result of increased 
membrane-bound ACE2 and ADAM-17, which is associated with an increase in 
host susceptibility to SARS-CoV-2 infection. The soluble ACE2 does not have an 
apparent direct role in the pathogenesis of COVID-19 since membrane-bound 
ACE2 is required for receptor mediated endocytosis of the virus. However, the 
soluble ACE2 has a protective role which is implicated by the binding of the soluble 
ACE2 to SARS-CoV-2 and sequestrating it away from the membrane bound ACE2 
to prevent viral entry and the initiation of the virus pathogenesis [61]. In this regard 
recombinant human ACE2 could be used as a therapeutic candidate to control 
SARS-CoV-2 invasion.  
Systemic injuries that were reported during SARS-CoV and SARS-CoV-2 
were mostly related to ACE2 function and its expression in different tissues. The 
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binding of SARS-CoV to ACE2 receptor was found to reduce its expression, which 
further induces acute lung injury in wild type mice, when compared to ACE2 
knockout mice, which indicates that acute lung injury during SARS-CoV is related 
to ACE2 expression level and this could also apply for SARS-CoV-2 [62]. 
Moreover, due to the high expression of ACE2 on cardiac cells, cardiac injury was 
reported among SARS-CoV [63] and SARS-CoV-2 [64] infected patients which 
was associated with increased disease severity along with high disease mortality. In 
addition, increased expression of ACE2 receptor in the kidney makes it highly 
vulnerable to be infected with SARS-CoV and SARS-CoV-2 leading to kidney 
injury [65]. A study was conducted by Hirsch et al. in New York where they found 
that acute lung injury among COVID-19 patients could reach up to 36.6% [66]. 
Other body organs, including the pancreas [67] [68], central nervous system [69], 
and endothelial cells [70] are also affected by coronavirus infection due to the 
differential regulation and expression of the ACE2 receptor.  
Transmembrane serine protease type 2 (TMPRSS2) is an androgen-
dependent serine protease that is encoded by chromosome 21. TMPRSS2 is mainly 
expressed on prostatic epithelial cells, where they play a role in the pathogenesis of 
prostate cancer [71]. Furthermore, TMPRSS2 is also expressed on kidney cells, 
digestive tract, and cardiac cells [10]. In addition, this protein is found to be highly 
expressed in the nose [72], and the upper respiratory tract [10]. This serine protease 
is found to have a role in the pathogenesis of certain viruses, including influenza 
viruses and coronaviruses, mainly through the cleavage of viral envelope 
glycoprotein which facilitates viral entry into hosts’ cells [10, 11]. In a recent cell 
culture analysis, it was found that cells expressing TMPRSS2 are highly susceptible 
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to SARS-CoV-2 infection [14]. Furthermore, serine protease inhibitors block S 
protein priming and subsequently it blocks viral entry and reduces infection, which 
suggest the importance of TMPRSS2 protease cleavage of S1 glycoprotein for 
infection [11].  
 
2.6 COVID-19 pathogenesis  
The global pandemic of COVID-19 spurred the need to determine the 
pathogenesis of the disease, which would eventually help in disease management. 
Currently the pathogenesis of the novel coronavirus is mainly derived from 
knowledge from previously known coronaviruses including SARS-CoV and 
MERS-CoV. In 2003, during the SARS-CoV outbreak, it was reported that SARS-
CoV entered into human cells through binding of its spike protein to specific hosts’ 
cell surface receptors, particularly ACE2 [73]. Similarly, Zhou et al., found that the 
novel SARS-CoV-2 only infected cells expressing ACE2 receptors, and the absence 
of this receptor prevented viral entry into host cells, confirming that ACE2 receptor 
is required for SARS-CoV-2 pathogenesis [9]. The receptor binding domain of 
SARS-CoV-2 spike protein interacts with the ACE2 receptor, particularly to 
subdomain I, activating ACE2 in a peptidase-independent manner [74]. 
Furthermore, for the successful viral entry into the host cells, the spike protein must 
be first cleaved at the S1/S2 site for priming and then at S’2 for activation, where 
S1 is required for recognition and S2 for fusion to the host membrane through 
mediating irreversible conformational changes. The cleavage of S glycoprotein is 
found to be achieved through the involvement of transmembrane proteases like 
transmembrane protease serine 2 (TMPRSS2) [11]. After the successful entry of the 
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virus to the host cells via ACE2 and TMPRSS2, additional viral proteins are 
synthesized including the replicase-transcriptase complex, which enables the virus 
to replicate its genome through RNA-dependent RNA polymerase. Later viral 
structural proteins are synthesized for assembly and the release of viral particles 
[75].  
 
2.7 Host response to SARS-CoV-2  
Symptomatic cases of SARS-CoV-2 are mainly associated with respiratory 
symptoms, that range from mild to moderate to severe respiratory distress syndrome 
with multi-organ failure. The common respiratory symptoms are due the increased 
expression of its target receptor ACE2 in the respiratory airways, which facilitates 
viral entry that result in lung damage. Moreover, immune system activation due to 
the presence of any pathogen would eventually augment the tissue damage and the 
onset of disease manifestations. The host immune system is activated when any 
pathogen, a virus in this case, makes it into the cells, which is subsequently 
recognized by the immune system cells, leading to the activation of both innate and 
the adaptive immune response. The presence of a virus or viral particles are first 
recognized by innate immune cells through pathogen recognition receptors, 
particularly Toll-like receptors (TLR), including TLR-3, TLR-7, and TLR-8, and 
this will lead to the activation of signaling pathways and the production of 
interferons (IFNs) [76]. Antiviral IFN is an important mediator to combat infection, 
through immune modulation, restricting cells proliferation and inducing apoptosis 
[77]. Moreover, alveolar macrophages and dendritic cells (DC) are the main innate 
immune cells in the respiratory airways, which upon activation result in the 
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production of inflammatory cytokines as well as function in antigen presentation 
that is needed for further activation of adaptive immune cells. At the site of 
infection, antigen presenting cells (APC) take up the virus and process it, and 
subsequently express the viral antigen, mainly S and N structural proteins [78], on 
its surface through MCH-I and MHC-II. Dendritic cells with the viral antigen travel 
through the lymph to the draining lymph nodes where they present the antigen to 
naïve T-cells. The interaction between APC peptide-bound MHC-I or MHC-II with 
T-cell receptor (TCR) aids in the activation of cytotoxic T-cells (CD8+ T-cells), 
which are able to kill infected cells directly or helper T-cells (CD4+ T-cells) that 
can induce immune response and activate B-cells to produce antibodies, 
respectively [79]. Severe cases of COVID-19 among adults were associated with 
over-activation of immune system and the increased production of inflammatory 
mediators including, interlukin-6 and 10 (IL-6 and 10), monocyte chemoattractant 
protein-1 (MCP-1), granulocytes colony stimulating factor (G-CSF), along with 
tumor necrosis factor- (TNF-). The higher the level of IL-6 was associated with 
increased disease severity. Also, these patients experienced a reduction in the 
number of lymphocytes in their peripheral blood, which could be the reason behind 
disease severity [80] [81]. Lung infiltration with inflammatory cells, mainly 
neutrophils and T lymphocytes, was reported among the severe cases [82]. 
Furthermore, in SARS-CoV-2 infection, the expression of MHC molecules on APC 
was found to be altered, which could affect host’s immune response. In a recent 
study, it was found that the increased production of inflammatory mediators, mainly 
IL-6, is associated with reduced expression of HLA-DR in CD14+ monocytes in 
the plasma samples of COVID-19 patients [83]. Enhanced inflammatory response 
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to SARS-CoV-2 affects host immune system negatively, increasing disease 
severity, and rendering the host more susceptible to bacterial infections. The 
adaptive immune response to SARS-CoV-2 was assessed among 20 positive cases 
[84]. They found that COVID-19 patients have an enhanced activity of both T and 
B cells mainly against S, N, and M proteins of SARS-CoV-2. However, they found 
that individuals unexposed to SARS-CoV-2 had the same specific CD4+ T-cells 
response, illustrating cross-reactivity to other coronaviruses. Furthermore, in 
association to activated CD4+ T-cells they reported an increase in anti-S IgG and 
IgA antibodies titer eliciting the involvement of humoral immunity. Furthermore, 
in another study, anti-S IgG was detected in all of the patients tested, while only 
some had anti-S IgM, anti-N IgG and anti-N IgM [85]. Moreover, Guo et al., 
assessed the production of SARS-CoV-2 IgM, IgA and IgG antibodies in 208 
plasma samples post-infection, using indirect ELISA. They found that IgM and IgA 
were detected 5-days after the onset of disease symptoms, while IgG was detected 
14-days post infection [86]. Non-respiratory symptoms, for instance thrombosis and 
pulmonary embolism, were also reported, especially among those with severe cases 
of COVID-19. Since it has been reported that endothelial cells also express ACE2 
receptor, this predisposes endothelial lining to SARS-CoV-2, damaging these cells 
and leading to the loss of the endothelial role in regulating blood clotting, inducing 
the formation of thrombi. These findings are consistent with the increased level of 






2.8 Probable justifications for the differences between adults and children 
with COVID-19  
The rate of COVID-19 cases and its clinical presentations is different in 
pediatric patients versus adults. Children are having lower rates of infection with 
SARS-CoV-2 and usually experience an asymptomatic course of the infection. 
There is no confirmed explanation, but several hypothetical explanations have been 
considered. The first explanation for this variation could be simply because schools 
were closed at the start of this pandemic and it was a holiday season in China, which 
reduced the exposure of the pediatric population to the novel coronavirus. The 
second hypothesis to this variation could be related to differences in the immune 
system response of both children and adults. With the continuous exposure to 
antigens, adult and older individuals experience exhaustion of naïve T-cells and the 
increase in the number of effector and memory T-cells [88], which is associated 
with an increase in the production of proinflammatory cytokines causing cytokine 
storms that worsen the disease condition. Also, aging was reported to be associated 
with reduction in the expression of costimulatory molecules including CD27 and 
CD38, that render them more susceptible to infection [89]. On the other hand, the 
immune response during infancy is strongly regulated by differences in the 
activation of Toll-like receptor pathways and the production of regulatory mediators 
and cells. Early after birth, there is a decrease in the expression of proinflammatory 
cytokines by impaired CD4+ Th1 cells, and reduced expression of cytotoxic 
mediators by CD8+ T-cells [90]. Moreover, lung immune system in children is 
suppressed by increased number of regulatory T cells there [91], further reducing 
disease complication. The third hypothesis is the presence of other respiratory 
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viruses in the children’s airways [92] could compete with SARS-CoV-2 and limit 
the growth of the virus, subsequently lowering the rate of COVID-19 cases among 
children.  
Furthermore, the differential expression of ACE2, which is the SARS-CoV-
2 target receptor, among children and adults could be one of the explanations. ACE2 
expression levels among children could be less than that in adults, as it was reported 
previously that ACE2 expression is higher in well differentiated lung cells and 
children’s lung epithelial cells continue to mature after birth [58]. Furthermore, in 
a recent study Bunyavanich et al., a retrospective analysis of ACE2 expression in 
the nasal epithelium of 302 subjects from an asthma cohort, with age ranging from 
4 to 60 years old, they found that ACE2 expression levels are lower among children 
when compared to the adults, and this expression was found to increase with age 
[13]. The public gene expression dataset was used to explore the expression of 
hosts’ receptor genes in the respiratory tract that have been reported to be involved 
in the pathogenesis of SARS-CoV-2, namely ACE2 and TMPRSS2. It was found 
that children have lower expression of ACE2 along with TMPRSS2 in the lung 
airways [15]. However, Chen et al., combined the public genomics, epigenomics 
and transcriptomic records of ACE2, and they found that ACE2 receptor is high 
among children and this expression decreased with age, which is opposing to other 
studies, suggesting that this receptor could have a protective role instead to SARS-






2.9 Laboratory diagnosis   
 Upper respiratory tract specimens are routinely collected for COVID-19 real 
time reverse transcription-polymerase chain reaction (real time RT-PCR). The CDC 
recommended nasopharyngeal specimens as an ideal specimen for testing [94]. But, 
if it difficult to obtain, then other respiratory specimen would be appropriate, such 
as nasal swab, oropharyngeal specimen, and nasal and nasopharyngeal wash or 
aspirate. The specimens should be collected using a swab with appropriate viral 
transport media or in a sterile container and transported to the lab as soon as possible 
for testing. Blood samples can be also collected in case if serological testing is 
required. Furthermore, it was also found that SARS-CoV-2 is also identified in anal 
swabs and urine samples apart from respiratory specimens by RT-qPCR, but with 
varying viral loads [95]. Real time RT-PCR is considered as the most important 
method among the techniques that are used to detect coronaviruses, because of 
higher sensitivity and because the amplification and the analysis occur in a closed 
system which minimizes the risk of contamination and laboratory hazards [96]. 
There are various PCR assays that detect the presence of SARS-CoV-2 by detecting 
different viral genetic targets including genes for helicase, nucleocapsid, 
transmembrane, envelope, spike protein, open reading frames (ORF1a and ORF1b), 
and RNA-dependent RNA polymerase (RdRp) [97]. Furthermore, it is 
recommended to use at least two targets, one targeting a conserved region and 
another targeting a more specific region to avoid the effect of genetic drift since 
may occur as the virus evolves. The viral RNA is measured through PCR cycle 
threshold (Ct-value), which represent the number of amplification cycles required 
for the fluorescent signal to cross the assay threshold and be detectable. 
  
26 
Furthermore, an immunological assay can be used to identify the existence of 
antibodies against SARS-CoV-2. However, antibodies may not be detectable if 
tested too early during the symptomatic period [98] and a positive antibody test may 
rather indicate past infection.  
2.10 COVID-19 Treatment  
 To date there is no definite treatment that is effective for SARS-CoV-2 
infection. Symptomatic positive cases are treated with antibiotics, antiviral therapy, 
and corticosteroids. Moreover many COVID-19 patients are also under oxygen 
therapy and only the severe cases are managed with mechanical ventilators [99]. 
The National Health Commission and State Administration of Traditional Chinese 
Medicine recommended certain antivirals for the management of COVID-19, such 
as interferon alfa (IFN-), ribavirin, lopinavir, arbidol chloroquine phosphate and 
tocilizumab in the presence of increased IL-6 that led to lung injury in critical cases. 
Furthermore, traditional Chinese medicine was also suggested to be used as a 
potential treatment for COVID-19, as in vitro studies showed the presence of anti-
SARS-CoV-2 substances in Chinese herbs that were previously used for the 
treatment of other respiratory infections [100]. Furthermore, there are other drugs 
that are recommended as potential treatment for SARS-CoV-2 infection, including 
certain antimalarial drugs (chloroquine, hydroxychloroquine), antivirals 
(remdesivir and favipiravir), along with convalescent sera from recovered 
individuals and many more, but still they are under investigation and their efficacy 
should be confirmed by preclinical and clinical trials. Wang et al., and Yao et al., 
showed that antimalarial chloroquine is able to prevent SARS-CoV-2 infection in 
vitro studies, yet the mechanism behind this is not known [101] [102]. Clinical trials 
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of chloroquine have shown that it is effective in inhibiting pneumonia, improving 
lung image and reducing disease severity among 100 COVID-19 patients [103]. In 
the same study, none of the subjects experienced adverse reaction, yet the US 
restricted the use of chloroquine due to the cardiac toxicity concerns. Furthermore, 
remdesivir is an antiviral drug that was found to limit coronavirus infection in vitro 
[101], and it showed beneficial responses in a COVID-19 patients in US [104], but 
clinical trials are on-going to ensure the safety and efficacy of such treatment. 
Moreover, favipiravir is an antiviral agent that functions in inhibiting RNA-
dependent RNA polymerase from RNA viruses [105], therefore this drug could 
have an therapeutic role against SARS-CoV-2. Furthermore, clinical trials on 
favipiravir showed that it is more efficient with no side effects compared to patients 
treated with lopinavir/ritonavir and it is preferred when comparing to arbidol [106]. 
Convalescent plasma from recovered individuals can be used as treatment. During 
SARS-CoV infection convalescent plasma was used to treat patients, and it was 
effective in reducing the viral load one day after transfusion [107]. Shen et al., 
showed that the treatment of severely diseased COVID-19 patients with plasma 
from recovered individuals was associated with normalization of body temperature 
and reduction in the total viral load, yet its safety is under investigation [108].  
 Vaccination is required to prevent infections and its associated morbidities, 
by the production of memory B and T cells, so that whenever the body encounters 
the same infectious agent, the immune system recognize it rapidly and destroy it, 
before affecting the host. Currently there are accepted vaccines for SARS-CoV-2 
pandemic. At the beginning of this pandemic there were evidence that the live 
attenuated strain, which is known as Bacille Calmette-Guerin of M. bovis is used 
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against tuberculosis, may be useful in preventing COVID-19. In vivo and in-vitro 
studies showed that it protects against respiratory infections and it has been 
hypothesized that it would partially protect against SARS-CoV-2 infection [109]. 
Other vaccines include artificial antigen presenting cells vaccine, which are 
lentiviral-based vectors that are made to express viral proteins and immune 
modulatory genes to aid in the T-cells activation, and currently it is in the clinical 
trial phase I [110]. Recombinant adenovirus-5 vector, it is genetically engineered 
so that it is replication defective, and it expresses viral S protein. Hyperimmune 
plasma, is heat-inactivated plasma of people who were previously positive for 
SARS-CoV-2, were also used as one of the disease management strategies [111]. 
Moreover, two newly developed vaccines that are based on mRNA sequences that 
codes for viral protein once inside the host cells showed high efficacy in phase III 
clinical trials. Pfizer and BioNTech and US pharmaceutical company Moderna both 
generated mRNA vaccines that codes for the viral spike glycoprotein, as an antigen 
to trigger host immune responses against the virus [112]. Currently the FDA 
approved the use of both Pfizer/BioNTech and Moderna COVID-19 vaccines. 
These two vaccines have shown to protect individuals from SARS-CoV-2 infection, 
by the formation of antibodies against SARS-CoV-2. Adverse events have been 
reported with both the vaccine, but higher rates of adverse events have been more 
reported among those who are vaccinated with Moderna [113]. Moreover, 
chimpanzee adenovirus-vectored vaccine that expresses SARS-CoV-2 spike 
protein showed an acceptable cellular and humoral immune responses along with 




Chapter 3: Materials and Methods  
3.1 Material  
3.1.1 kits 
All TaqMan assays were purchased from ThermoFisher Scientific for gene 
expression assays.  
 ACE2 TaqMan Gene Expression Assays were obtained (ACE2-1: 
Catalog number: 4331182, assay ID: Hs01085333_m1, ACE2 target is 
located at exon 17-18 boundary (NCBI reference sequence, 
NM_021804.2) within the transmembrane domain of ACE2), and 
(ACE2-2: Catalog number: 4331182, assay ID: Hs00222343_m1, ACE2 
target is located at exon 8-9 boundary (NCBI reference sequence 
NM_021804.2) within the transmembrane domain of ACE2).  
 TMPRSS2 TaqMan Gene Expression Assays (Catalog number: 
4331182, assay ID: Hs01122322_m1, TMPRSS2 target is located at 
exon 10-11 boundary (NCBI reference sequence, NM_001135099.1)) 
  ACTB TaqMan Gene Expression Assays (Catalog number: 4331182, 
assay ID: HS01060665_g1, ACTB target is located at exon 2-3 
boundary (NCBI reference sequence, NM_001101.3)) 
 TaqPath 1-Step RT-qPCR MasterMix (REF: A15300) 
 
3.2 Methods  
Prior to initiating this study, ethical approval and a waiver of informed 
consent was obtained from the Institutional Review Board of Sidra Medicine and 
Qatar University (Appendix). All the research procedures were performed in 
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compliance with the appropriate ethical guidelines and regulations. 
 
3.2.1 Sample and data collection  
 At the beginning of COVID-19 pandemic in 2020, Sidra Medicine, which 
is a pediatric care hospital in Qatar, was deemed a COVID-19 free facility. 
Therefore, from April 2020 all the patients and their companion adult family 
members coming to Sidra Medicine were screened for COVID-19 through RT-
qPCR testing of nasopharyngeal swab specimens. Subsequently, from June to 
December 2020, residual nasopharyngeal swab specimens collected in universal 
viral transport media for COVID-19 testing, and those that met the inclusion criteria 
of the current study were identified and included in this study. The inclusion criteria 
included: at least one of the family members tested positive for COVID-19 by RT-
qPCR, at least 0.5ml of nasopharyngeal swab specimens were available for the child 
and the companion adult family member. The required COVID-19 positive and 
negative nasopharyngeal swab specimens for children and their companion adults 
were identified by querying the hospital infection prevention and control records 
and in patient’s electronic medical records (Power Chart, Cerner). Additional 
unpaired COVID-19 positive pediatric and adults who were symptomatic, were 
identified, and their residual nasopharyngeal swab specimens were obtained for this 
study. Only residual specimens were used in the study. Specimens were aliquoted 
from the viral transport media into labelled 2-ml tubes and were stored at -80C for 
further analysis. Moreover, since Sidra Medicine is a pediatric hospital, clinical and 
laboratory data related to positive pediatric patients included in this study were 
obtained through reviewing patient’s charts. A spreadsheet was created on a secure 
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network drive, accessible only to the research investigators, to save all the required 
information regarding the study samples; including patient medical record number, 
specific specimen identification number, assigned specific study ID, the storage 
location, gene expression data, clinical and laboratory data. To maintain patient 
anonymity, all patient identifiers were removed from the copy of the spreadsheet 
that was used for data analysis. 
 
3.2.2 Nucleic acid (RNA) extraction  
Total RNA from nasopharyngeal swab specimen was extracted using the 
Thermo Scientific Kingfisher Flex System platform, that uses magnetic particles 
for RNA purification. Extraction was performed as per the manufacturer’s protocol 
(ThermoFisher, Catalog no. N07669). All the reagents used in this procedure were 
obtained from ThermoFisher and are stored at room temperature. This procedure 
starts with preparing processing plates according to the number of samples that are 
going to be extracted in one run, and each of these plates has a specific reagent, 
with specific volume and a position in the Kingfisher machine. First all 96 deep 
well plates are labelled based on the reagent that will be added to them and they are 
prepared according to (Table 2). 
 
Table 2. Preparation of KingFisher processing plates. 
Plate ID Reagent Volume per one 
well 
Plate position 
Wash 1 plate Wash buffer 1 500 L 2 
Wash 2 plate 80% ethanol 1000 L 3 
Elution plate Elution buffer 50 L 4 
Tip comb plate A Kingfisher 96 tip comb are place in a 





After preparing the processing plate they are covered with adhesive seal and 
kept at room temperature until the sample plate is prepared. Another Kingfisher 96 
deep well plate is labelled as sample plate and 5 L of proteinase K is added to each 
well. Meanwhile, the frozen samples are allowed to thaw at room temperature, 
vortexed and 200 L of each sample is added to a specific well. Then binding bead 
mix is prepared (as shown below in Table 3) and 275 L of the mix is added to each 
sample well. 
 
Table 3. Binding bead mix preparation. 
Component Volume per well 
Binding solution 265 L 
Total Nucleic Acid Magnetic Beads (mix 
well before using) 
10 L 
Total volume per well 275 L 
 
 
Then KingFisher Flex instrument is switched on and the RNA extraction 
protocol is selected. The instrument door is opened by sliding the plastic cover and 
all the prepared plates are loaded in the instrument after the removal of the adhesive 
seal into their specific locations as indicated by selected protocol. The sample plate 
is loaded in position 1, wash 1 plate is in position 2, wash 2 plate is in position 3, 
elution pate is loaded in position 4 and the tip combs in the microplate are loaded 
in position 5. Then the instrument door is closed, and the start button is pressed. 
This platform of extraction takes around 23 minutes and once it is done the elution 




3.2.3 Real-time reverse-transcriptase quantitative polymerase chain reaction 
(RT-qPCR) 
The extracted nucleic acids are used for gene expression analysis for ACE2, 
TMPRSS2 and ACTB genes (Thermofisher) using pre-designed TaqMan gene 
expression assays. This is performed by real-time RT-qPCR in a MicroAmp Fast 
96-well reaction plate (Applied Biosystems) using the Applied Biosystems 7500 
Fast Dx system. All the reagents of TaqMan assay are allowed to thaw in room 
temperature prior to starting. The Master Mix for each of the target genes are 
prepared according to the number of samples in each run as shown in table 4.  
 
Table 4. Reaction master mix preparation. 








1 L x sample 
no. 
5 L x sample no. 4 L x sample no. 
TMPRSS 
(Hs01122322_m1) 
1 L x sample 
no. 
5 L x sample no. 4 L x sample no. 
ACTB 
(Hs01060665_g1) 
1 L x sample 
no. 
5 L x sample no. 4 L x sample no. 
 
Each reaction well has a total volume of 20 L, which contains 10 L of 
prepared reaction master mix (that contain specific gene Taqman assay, 4x Taqpath 
1-Step RT-qPCR master mix and nuclease free water) with 10 L of sample extract. 
The PCR plate containing the reaction mixture is placed in ABI7500 thermal cycler 
and the following program was set:  
 Holding stage:   
o 25.0 C for 02:00 minutes 
o 50.0 C for 15:00 minutes  
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o 95.0 C for 02:00 minutes  
 Cycling stage (40 cycles) 
o 95.0 C for 00:03 seconds 
o 60.0 C for 00:30 seconds  
 
3.2.4 Statistical analysis  
Descriptive statistics are used to describe the study population and their 
COVID-19 infection status. Distribution of data was tested by D'Agostino & 
Pearson test. The mean (SD) transcript levels for ACE2 and TMPRSS2 for 
COVID-19 positive adults and paired COVID-19 negative children from the same 
families was determined and compared by Wilcoxon Signed-Rank Test. Also, the 
statistical difference of ACE2 and TMPRSS2 expression between unpaired data 
groups was determined using Mann-Whitney U test. Logistic regression analysis 
was done to determine i) association between the expression of ACE2 and 
TMPRSS2 with SARS-CoV-2 RT-qPCR results (as dependent variable) for the 
overall population and for different age groups ii) association between the 
expression of ACE2 and TMPRSS2 with patient groups who were negative, 
asymptomatic or symptomatic with COVID-19 (as dependent variable). All 
statistical analysis in this study is carried out using SPSS and Graphpad Prism 9 
software. For all the performed tests, a p-value less than 0.05 was considered 






Chapter 4: Results 
4.1 Study subject demographics  
Residual nasopharyngeal swab specimens were obtained from children 
along with their companion adults, with history of SARS-COV-2 infection in at 
least one of the family members (paired samples). Beside the paired samples that 
were asymptomatic at the time of COVID-19 testing, additional unpaired samples 
from COVID-19 positive children and adults with known history of COVID-19 
associated symptoms were also obtained and included in the analysis. A total of 241 
nasopharyngeal specimens were included in this study, of which 207 samples were 
paired samples from 92 families in which at least one member was positive for 
SARS-COV-2 infection, consisting of 92 children and 115 adult companions. 
Furthermore, 24 and 10 COVID-19 positive unpaired nasopharyngeal swab 
specimens from pediatric and adults, respectively, were later included in this study. 
Nasopharyngeal swab specimens were available from more than one adult 
companions from 23 families. Among the study subjects, 63.2% of the adults and 
47.4% of the children were of female sex. The median age of the study children and 
adults were 4 (IQR: 1.4-7) and 34 (IQR: 30-39), respectively, and 59.5% and 64.8% 
were COVID-19 positive children and adults, respectively. In most of our paired 
samples, the child was paired with the mother for paired data analysis, but in some 
cases, where the mother was negative, or the sample for the mother was not 
available, then the child is paired with other family member. 




Table 5. Study subjects characteristics 
Categories Adult Children 
No. of samples 125 116 
Sex, n (%) Female 79 (63.2)  55 (47.4) 
Male  46 (36.8) 61 (52.6) 
Age, median (IQR) 34 (30-39) 4 (1.4-7) 
COVID-19 
result, n (%) 
Negative 44 (35.2) 47 (40.5) 
Positive 81 (64.8) 69 (59.5) 
 
4.2 Transcript level of -actin, ACE2 and TMPRSS2 in nasopharyngeal swab 
specimens  
 The reaction conditions were optimized for the purchased TaqMan assays, 
two ACE2 targets, ACE2-1 and ACE2-2 (Hs01085333_m1 and Hs00222343_m1, 
respectively), one target for TMPRSS2 (Hs01122322_m1) and -actin (ACTB) 
(HS01060665), by using 10 nasopharyngeal swab specimens (5 COVID-19 positive 
and 5 COVID-19 negative). One of the ACE2 targets (ACE2-1, Hs01085333_m1) 
was consistently giving stronger Ct values than the other ACE2 target (mean Ct, 
32.82.6 vs 34.72.2, p<0.001 by paired sample T-test) (Figure 4), therefore ACE2-
1 was chosen for the gene expression analysis for this study. The expression of the 
endogenous control -actin gene was detected in all of analyzed nasopharyngeal 
specimens. Furthermore, the transcript levels of -actin were normally distributed 
among all the specimens by D’Agostino and Pearson normality test (K2 = 0.2395; 
p= 0.8871). Moreover, the mean Ct value of -actin were not significantly different 
among positive COVID-19 cases and negative COVID-19 patients (p=0.5623; 
unpaired 2 tailed T-test). Yet, the mean Ct values of -actin in nasopharyngeal 
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specimens from children (25.1±2.9) were significantly stronger than that from 
adults (26.7±2.5) (p<0.0001; unpaired 2-tailed T-test) (Figure 5). On the other hand, 
Ct for ACE2 and TMPRSS2 are not normally distributed (K2=18.5; p<0.0001 for 
ACE2 and K2=6.3; p<0.042 for TMPRSS2), hence nonparametric tests including 
Mann Whitney U test and Wilcoxon matched pairs signed ranked test were chosen 
to compare unpaired and paired data, respectively. In addition, the RT-qPCR Ct 
value for ACE2 and TMPRSS2 for a number of specimens remained undetermined. 
Among 241 nasopharyngeal swab specimens, 143 and 45 specimens remained 
undetermined for ACE2 and TMPRSS2 gene expression, respectively, with 40 
samples with undetermined results for both ACE2 and TMPRSS2. Of the 143 
specimens that were undetermined for ACE2, 83 were SARS-COV-2 positive, and 
among the undetermined TMPRSS2, 25 were positive for COVID-19. Therefore, 
for quantitative data analysis, a Ct value of 40 was assigned to these specimens. For 
the specimens in which ACE2 and TMPRSS2 transcript levels were not detectable, 
it was expected that relative gene expression of these genes can still be calculated 
using the assigned value because of the variation in qPCR Ct for -actin. Based on 
the gene expression analysis by RT—qPCR Ct values, the relative transcript levels 
of ACE2 (mean CtSD, 37.73.5) and TMPRSS2 (mean CtSD, 35.43.5) were 
much weaker and more variable when compared to the transcript levels of -actin 






Figure 4: Transcripts level of two ACE2 targets (ACE2-1 and ACE2-2) by RT-
qPCR for assay optimization.  
Two ACE2 targets were initially evaluated in this study for higher sensitivity and 
ACE2-1 assay was found to generate stronger Ct values for ACE2 when compared 







Figure 5: Comparison of -actin gene expression between adults and children and 
between COVID-19 positive and negative participants 
Mean qPCR Ct values for -actin gene in different groups with 95% CI. p-value are 




Figure 6: -actin, ACE2 and TMPRSS2 gene expression in nasopharyngeal swab 
specimens among all study subjects. 
The data show mean Ct values of all three target genes with 95% confidence 
interval, n=241.  
 
 
4.3 Transcript levels of ACE2 and TMPRSS2 in SARS-CoV-2 exposed 
families nasopharyngeal swab specimens relative to -actin 
 In this study, 207 paired samples from children and their companion adults, 
where at least one of them is positive for SARS-CoV-2 infection, were involved in 
the gene expression analysis for ACE2, TMPRSS2 and the background reference 
gene -actin. The raw Ct values obtained from RT-qPCR for both ACE2 and 
TMPRSS2 were normalized by subtracting the Ct values from ACE2 and 
TMPRSS2 from the Ct values from the respective -actin gene’s Ct value, in order 



















each of the nasopharyngeal samples, subsequently the Ct values for ACE2 and 
TMPRSS2 relative to -actin are used in all of the following statistical comparisons. 
The transcript levels of ACE2 and TMPRSS2 were compared for the paired 
samples, and the expression of both of the genes were significantly higher 
(p=0.0034 and 0.0174, for ACE2 and TMPRSS2, respectively, by Mann Whitney 
U test) in the adults in comparison with the children (Figure 7).  
 
 
Figure 7: Expression of ACE2 and TMPRSS2 genes in children and adults within 
families exposed to SARS-CoV-2 relative to -actin.  
Comparison between the transcript levels of ACE2 and TMPRSS2 in paired 
nasopharyngeal swab specimens relative to -actin. The data shows mean Ct values 
with 95% CI, n=115 adult and 92 children. P-values were computed by Mann 




Furthermore, among the same 207 paired samples the transcript levels of 
ACE2 and TMPRSS2 were assessed, and they were not significantly different 
between positive and negative COVID-19 subjects (p=0.0771 and 0.3518, for 
ACE2 and TMPRSS2, respectively, by Mann Whitney U test), or among the adult 
subjects only (p=0.3817 and 0.7288, for ACE2 and TMPRSS2, respectively, by 
Mann Whitney U test), or pediatric subjects (p=0.2490 and 0.3963, for ACE2 and 
TMPRSS2, respectively, by Mann Whitney U test). Moreover, no significant 
difference was obtained between COVID-19 positive versus COVID-19 negative 
children from families where one of the adult companions is positive for SARS-
COV-2 (p=0.1218 and 0.2263, for ACE2 and TMPRSS2, respectively, by Mann 
Whitney U test), and COVID-19 positive versus COVID-19 negative adults where 
the child tested positive for SARS-COV-2 (p=0.3120 and 0.3350, for ACE2 and 
TMPRSS2, respectively, by Mann Whitney U test) (data summarized in table 6, by 
Mann Whitney U test). No difference (p>0.05) was observed in the ACE2 and 










Table 6. ACE2 and TMPRSS2 gene expression in the nasopharyngeal samples of 
COVID-19 positive Versus negative patients. 





Overall  ACE2 -11.24.364 -12.383.755 0.0771 
TMPRSS2 -9.1863.724 -9.8183.963 0.3518 
Adult ACE2 -10.544.466 -11.623.250 0.3817 
TMPRSS2 -8.7543.548 -8.8543.438 0.7288 
Children ACE2 -12.264.024 -13.094.080 0.2490 
TMPRSS2 -9.8683.929 -10.724.238 0.3963 
Adult in families 
with at least one 
positive child 
ACE2 -10.494.231 -11.863.176 0.3120 
TMPRSS2 -8.3533.929 -9.4423.349 0.3350 
Children in families 
with at least one 
COVID-19 positive 
adult 
ACE2 -11.383.984 -13.094.08 0.1218 
TMPRSS2 -9.0283.869 -10.724.238 0.2263 
 *p-values were calculated by two tailed, Mann-Whitney U test 
#Ct values were calculated by subtracting the Ct values for ACE2 or TMPRSS2 





4.4 Paired analysis of transcripts levels of ACE2 and TMPRSS2 among 
children and adults from the same families  
 Additionally, among the paired study subjects, particularly when comparing 
the relative expression of ACE2 and TMPRSS2 genes of COVID-19 positive adults 
versus COVID-19 negative children from the same families (n=94, 47 pairs), the 
transcript levels of both genes are significantly higher (p=0.0002 and 0.0061, for 
ACE2 and TMPRSS2, respectively, by Wilcoxon Signed-Rank test) in the adult 
member of the family compared to children (Figure 8). On the other hand, the 
expression of ACE2 and TMPRSS2 among COVID-19 positive adult versus 
COVID-19 positive Children (p=0.5477 and 0.2247, for ACE2 and TMPRSS2, 
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respectively, by Wilcoxon Signed-Rank test) (n=34, 17 pairs) (Figure 9A) and 
COVID-19 negative adult versus COVID-19 positive children (p=0.2946 and 
0.1782, for ACE2 and TMPRSS2, respectively, by Wilcoxon Signed-Rank test) 
(n=56, 28 pairs) (Figure 9B) within the same families, were not significantly 
different from each other (p>0.05). Furthermore, to assess if the significant 
difference in the gene expression was due to differences in the age distribution 
among the COVID-19 positive adults versus COVID-19 negative children within 
the same family, we compared the age distribution of the subjects involved in these 
groups. Yet, there was no significant difference (p=0.4081, by Mann-Whitney U-
test) between the mean or the median age of COVID-19 positive children 
(4.4024.197 years or 3 (1.04-7)) and COVID-19 negative children (5.3464.539 







Figure 8: Transcript levels of ACE2 and TMPRSS2 of COVID-19 positive adult 
versus COVID-19 negative children from the same family. 
The transcript levels of ACE2 and TMPRSS2 in the nasopharyngeal swab 
specimens of COVID-19 positive adults have been compared to negative children 
within the same family. A total number of 47 families, where the adult is positive, 
and the child is negative for SRAS-CoV-2. p-values were calculated from Wilcoxon 












Figure 9: Comparison pf transcript levels of ACE2 and TMPRSS2 among adults 
versus children from the same family. 
Comparison of the transcript levels of both ACE2 and TMPRSS2 in the 
nasopharyngeal swab specimens of (A.) COVID-19 positive adults versus COVID-
19 positive children and (B.) COVID-19 negative adults versus COVID-19 positive 
children within the same family. A total number of 17 families where the adult is 
positive, and the child is also positive for SARS-CoV-2 and 28 families where the 





Figure 10: Age distribution of COVID-19 positive and COVID-19 negative 
children.  
Comparison of age distribution among COVID-19 positive adults versus COVID-
19 positive children (n= 17) or COVID-19 negative children (n=47). Data shows 





4.5 Association of nasopharyngeal ACE2 and TMPRSS2 expression with 
SARS-COV-2 infection status 
 Age, sex and nasopharyngeal expression of ACE2 and TMPRSS2 were not 
significantly associated with SARS-CoV-2 infection status, by multivariate analysis 

































regression. However, by performing univariate regression analysis the odds ratio of 
SARS-CoV-2 positivity status was higher (odds ratio, OR: 1.074, 95%CI: 1.003-
1.154, p=0.0443) with higher expression of ACE2 (Table 7). Later we divided the 
entire paired sample population into two subgroups, subgroup 1; families where at 
least one adult member is positive for COVID-19 with positive or negative children, 
and subgroup 2; families with positive COVID-19 adults and negative children 
only. In subgroup 1 the odds of SARS-CoV-2 positivity was higher, with OR: 1.123 
and 1.107, with higher expression of ACE2 and TMPRSS2, respectively. 
Furthermore, in subgroup 2 the odds of SARS-CoV-2 positivity is even higher, with 
OR: 1.146 and 1.123, with higher expression of ACE2 and TMPRSS2. On the other 
hand, SARS-CoV-2 infection status was not significantly associated with ACE2 
and TMPRSS2 gene expression in the subgroup of families with at least one 
COVID-19 positive child with negative or positive COVID-19 adults (for ACE2; 
odds ratio, OR: 0.9712, 95%CI: 0.8669 – 1.085, p=0.6062, for TMPRSS2; odds 
ratio, OR: 1.017, 95%CI: 0.9100 – 1.139, p=0.7715, n=96), or in subgroups of 
families with COVID-19 positive children and negative COVID-19 adults only, (for 
ACE2; odds ratio, OR: 0.9243, 95%CI: 0.7941-1.069, p=0.2950, for TMPRSS2; 
odds ratio, OR: 0.9012, 95%CI: 0.7762 - 1.034, p=0.1498, n=60). In addition to 
SARS-CoV-2 infection status, these results also showed that ACE2 and TMPRSS2 
are significantly associated (OR: 1.115, 95%CI: 1.039-1.203, p=0.0034 for ACE2 
and OR: 1.112, 95%CI: 1.033-1.200, p=0.0055 for TMPRSS2) with the adult 
population, which is consistent with the data obtained from gene expression 
analysis (Figure 8). Yet, no significant association was found between gender and 
ACE2 and TMPRSS2 gene expression.  
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Table 7. Association of nasopharyngeal ACE2 and TMPRSS2 gene expression with 
SARS-CoV-2 infection status.  
Category 
Overall (n=207) 
Subgroup 1: Families 
with COVID-19 positive 
adults only (n=147) 
Subgroup 2: Families with 
COVID-19 positive adult 














































Simple logistic regression analysis, reference category is “COVID-19 negative” 
 
 
4.6 Association of nasopharyngeal ACE2 and TMPRSS2 expression with 
patient’s clinical presentation and laboratory findings  
Sidra Medicine is a designated COVID-19 free pediatric facility and only 
patients with no history of COVID-19 within the last two weeks or patients having 
no COVID-19 related symptoms are eligible for admission to the hospital. 
Therefore, all the patients and the visitors presenting to Sidra Medicine are triaged 
for a prior history of COVID-19 and COVID-19 associated symptoms, including 
temperature assessment, along with SARS-CoV-2 RT-qPCR testing. Hence, most 
of the paired children and adults included in this study are asymptomatic, except for 
10 children (out of 92 children and 115 adult) that had symptoms associated with 
SARS-CoV-2 infection, such as high body temperature (7/10), upper respiratory 
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tract symptoms including sore throat, cough, and runny nose (4/10) and 
gastrointestinal symptoms such as abdominal discomfort, vomiting and diarrhea 
(5/10). In order to further assess the association between the transcript levels of 
ACE2 and TMPRSS2 with the symptomatic cases of SARS-CoV-2 in comparison 
to the asymptomatic cases, we included additional unpaired COVID-19 positive 
symptomatic children and adults (n = 24, n = 10, respectively). First, we assessed 
the expression of ACE2 and TMPRSS2 among COVID-19 negative (n = 91) versus 
COVID-19 positive symptomatic (n = 44) and asymptomatic (n = 106) in the overall 
population (Figure 11 A), also we compared the expression of these two genes 
among COVID-19 negative (n = 47) versus positive symptomatic (n = 34) and 
asymptomatic (n = 35) children only (Figure 11 B), and in both classifications, there 
was no significant difference in the expression of these two genes across the groups. 
Among the total positive symptomatic cases (n=34, including paired and unpaired), 
29 only had fever, 19 with upper respiratory tract symptoms, and 13 with 
gastrointestinal symptoms.  
 




Figure 11: The transcript levels of ACE2 and TMPRSS2 relative to -actin in 
COVID-19 negative versus asymptomatic versus symptomatic cases.  
A. Transcript level of ACE2 and TMPRSS2 among COVID-19 negative versus 
asymptomatic versus symptomatic cases; n = 91 negative, 106 positive 
asymptomatic, and 44 positive symptomatic cases. B. Gene expression among 
COVID-19 negative versus asymptomatic versus symptomatic pediatric samples 
only, n = 47 negative, 35 asymptomatic, and 34 symptomatic. The data shows the 
mean with 95% CI, by One way ANOVA.  
 
 
Age, sex and nasopharyngeal expression of ACE2 and TMPRSS2 were not 
significantly associated with patients clinical presentation (symptomatic versus 
asymptomatic), by multivariate analysis of the overall paired study population 
Furthermore, we assessed the association of transcript levels of ACE2 and 
TMPRSS2 with each of the symptoms, including fever, upper respiratory tract 
symptoms, and gastrointestinal symptoms among the positive pediatric 
symptomatic patients only, using univariate logistic regression analysis, we 
excluded the symptomatic adults because the specific symptoms for these adults 
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were not documented the electronic medical record. There is no significant 
association between the expression of ACE2 and TMPRSS2 with fever, or upper 
respiratory tract symptoms, or gastrointestinal symptoms among positive children 
(n=68, with 34 symptomatic) and the overall positive population (n=150, with 44 
symptomatic) (Table 8).  
 
Table 8. Association of nasopharyngeal ACE2 and TMPRSS2 gene expression with 





























1.024 (0.9115 – 
1.153) 
0.6885 




1.033 (0.9191 – 
1.164) 




1.115 (0.9759 – 
1.288) 




1.029 (0.8930 – 
1.188) 
0.6911 0.9656 (0.8512 – 
1.097) 
0.5832 
Simple logistic regression analysis, all positive population (n = 150), and positive 
children only (n= 68). OR; odds ratio, CI; confidence interval, URTS; upper 





 In addition to the clinical presentations, few of the positive asymptomatic 
and symptomatic children had specific clinical laboratory test results for D-dimer, 
C-reactive protein (CRP), procalcitonin (PCT), ferritin, white blood cells (WBCs), 
platelets, lymphocytes, neutrophil, prothrombin time (PT), fibrinogen, troponin, N-
terminal pro b-type natriuretic peptide (NT-proBNP) (Table 9). There was no 
significant association between the nasopharyngeal expression of ACE2 and 
TMPRSS2 with at least one abnormal lab finding (n = 69, OR= 0.9807, p-value= 
0.7557, and OR= 1.035, p-value= 0.5485 for ACE2 and TMPRSS2, respectively). 
Moreover, among 22 COVID-19 positive children who were tested for CRP, 13 
were reported with abnormally high levels of CRP, but it was not significantly 
associated with the transcript levels of ACE2 and TMPRSS2 (p-value=0.9373, and 
0.7155 for ACE2 and TMPRSS2, respectively). Furthermore, complete blood count 
was performed for 28 COVID-19 positive children, and no significant association 
was found between nasopharyngeal ACE2 and TMPRSS2 with abnormal WBC 
(OR=1.014, p-value= 0.8738 for ACE2 and OR=1.010, p-value= 0.9162 for 
TMPRSS2), neutrophil (OR=1.030, p-value= 0.7377 for ACE2 and OR=1.107, p-
value= 0.3107 for TMPRSS2), lymphocyte (OR=1.041, p-value= 0.6667 for ACE2 
and OR=1.222, p-value= 0.0923 for TMPRSS2), and platelets (OR=0.9809, p-
value= 0.8226 for ACE2 and OR=1.026, p-value= 0.7868 for TMPRSS2). For the 
rest of the laboratory findings, they were tested only for few patients, and they are 






Table 9. Summary of patients tested for specific clinical laboratory tests. 
Laboratory test  Total no. of 
patients tested 
Normal High Low 
CRP  22 9 13 0 
D-dimer 3 0 3 0 
PCT 4 1 3 0 
Ferritin  3 0 3 0 
WBC 28 17 5 6 
Neutrophil 28 18 7 3 
Lymphocyte 28 20 0 8 
Platelets  28 17 5 6 
PT 9 4 4 1 
Fibrinogen 8 7 1 0 
Troponin  3 1 2 0 












Chapter 5: Discussion  
5.1 Association of ACE2 and TMPRSS2 expression with SARS-CoV-2 
infection status   
Since the start of COVID-19 outbreak, many studies have shown that people 
at any age can acquire the infection, but they are differentially affected by SARS-
CoV-2 infection. Lower rates of infection and milder COVID-19 presentation are 
reported more among children when compared to adults and elderly patients who 
experience higher mortality rates [12]. Many hypothetical explanations have been 
proposed, including the differential expression of specific proteins that are involved 
in the pathogenesis of SARS-CoV-2 infection. Moreover, several studies have 
explained the role of respiratory tract ACE2 receptor [9] and TMPRSS2 [11] in 
SARS-CoV-2 pathogenesis, based on the knowledge that was gained previously 
from SARS-CoV. However, little attention has been given to the role of ACE2 and 
TMPRSS2 protein in the nasopharyngeal epithelium. Nasopharyngeal expression 
of these proteins may have an essential role in SARS-CoV-2 transmission and 
infection, as the nasal cavity acts as one of the common routes for viral entry into 
the human body [44]. Therefore, in the current study, we conducted a case-control 
study to test our hypothesis that decreased expression of nasal or nasopharyngeal 
ACE2 is associated with a lower incidence of SARS-CoV-2 infection among 
pediatric population. To further understand the role of ACE2 in COVID-19 
pathogenesis, we also analyzed the expression of TMPRSS2, which is a proteolytic 
enzyme required for the activation of ACE2 receptor, facilitating SARS-CoV-2 
entry into host cells via the viral spike glycoprotein [11]. In the presented study, our 
target population are families where the members are differentially affected by 
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SARS-CoV-2, so that COVID-19 negative members in this setting would serve as 
an appropriate case-control for the study, since these individuals remained negative 
despite being exposed to the virus.  
 ACE2 receptors appear to be either soluble or membrane bound. In our study 
we specifically targeted the transmembrane protein, which have a role in viral entry 
in the host cells, in contrast to the soluble form of ACE2, which is purported to play 
a protective role in SARS-CoV-2 infection [115, 116]. In our study, nasopharyngeal 
expression of ACE2 was significantly higher in the adult group in comparison to 
the children, irrespective of SARS-CoV-2 infection status (Figure 7), which is 
consistent with the earlier report from a pre-COVID-19 asthma cohort that showed 
that nasopharyngeal ACE2 expression increases with age [13]. Furthermore, our 
study provides direct evidence that also the nasopharyngeal expression of 
TMPRSS2 is also significantly higher in the adults when compared to children 
(Figure 7). Since our study is particularly targeting families with at least one 
positive COVID-19 case, these findings together give a direct evidence that lower 
nasopharyngeal expression of ACE2 and TMPRSS2 is one of the reasons behind 
lower rates of SARS-CoV-2 infection among children, despite being in close 
contact to a positive family member. Moreover, these results are also consistent 
with the findings from a study conducted by Askari et al., where they used public 
gene expression datasets, and they reported that the expression of ACE2 and 
TMPRSS2 in the nasal and bronchial airways are lower among children when 
compared to adults [117]. Furthermore, it was previously reported that increased 
expression of ACE2 enhances viral entry [53, 54], along with higher expression of 
TMPRSS2 in cell culture analysis [118], increases the susceptibility of the host cells 
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to SARS-CoV-2 infection, thus, higher expression of these proteins among adults 
could render them more susceptible to SARS-CoV-2 infection. On the other hand, 
one study in the literature reported that by combining the public genomic, 
epigenomic and transcriptomic records of ACE2, it was found that ACE2 receptor 
expression is however higher in children and the expression decreases with age [93]. 
This variation could be explained by the fact that there are different types of ACE2; 
soluble and membrane bound, that could have different roles during infection, and 
more attention should be given to the type of ACE2 before interpreting gene 
expression.  
The expression of ACE2 and TMPRSS2 was not significantly different 
between COVID-19 positive versus COVID-19 negative groups among the overall 
study subjects, yet the mean transcript levels of both genes were consistently higher 
in the COVID-19 positive groups (Table 6). Statistical insignificance of these data 
may be related to the smaller population size of our study, which is also one of the 
major limitations of our study. Furthermore, apart from the nasopharyngeal 
expression of ACE2 and TMPRSS2, additional systemic factors may also be 
involved in SARS-CoV-2 pathogenesis. These factors may also account for the 
variation in disease presentation from one individual to another. Some examples of 
such differences may include differences in the immune response and cytokine 
production and regulation between adults and children [88] [90], the presence of 
other respiratory viruses in the airways of children,  which may compete with 
SARS-CoV-2 and limit its growth [92], and the presence of pre-existing cross-
reactive antibodies [119]. Yet, by logistic regression analysis the expression of 
ACE2 was positively associated with SARS-CoV-2 infection status, which further 
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indicates that the higher expression of ACE2 induce the incidence of SARS-CoV-
2 infection. This finding is consistent with the findings from an independent study 
that was conducted in British Columbia, Canada, which is currently in a pre-print 
status, where the expression of ACE2 was also positively associated with SARS-
CoV-2 infection status [120].  
  
Additionally, we compared the expression of ACE2 and TMPRSS2 between 
children with their companion adult family members, where the adult member was 
mostly the mother, expect in some families where the mother was negative, or the 
sample was not available, then we compared the child with other family members. 
By paired data analysis, we found that the expression of both receptors, ACE2 and 
TMPRSS2, was significantly greater among positive COVID-19 adults when 
compared to negative COVID-19 children from the same families (Figure 8). This 
finding was further supported by the result that was obtained from the association 
of ACE2 and TMPRSS2 expression, which were stronger in the subgroup of 
families with COVID-19 positive adults and COVID-19 negative children when 
compared to the overall study population (Table 7). The fact that the expression of 
these genes was not significantly different between COVID-19 positive adults 
versus COVID-19 positive children, although the expression of these genes was 
significantly different between overall adult and pediatric population further 
supports the role of nasopharyngeal expression of ACE2 and TMPRSS2 in COVID-
19 infection in children. On the other hand, the fact that there was no significant 
difference of transcript levels of ACE2 and TMPRSS2 in nasopharyngeal 
specimens from COVID-19 negative adults and COVID-19 positive children 
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suggests that the role of these proteins in acquiring COVID-19 infection may be 
more pronounced to the pediatric population. The involvement of other underlying 
differences in the host cells cannot be ruled out as well. For example, it was reported 
by Barker et al., that SARS-CoV-2 itself could induce the expression of ACE2 
[121], which could mask the differential roles seen between adults and children. 
Increased levels of interferon triggered by innate immunity that can also act as a 
transcription factor for ACE2 gene and subsequently it induces its expression 
during SARS-CoV-2 infection. Further investigates are required to confirm the role 
of all these factors in acquiring COVID-19 infection.   
 
5.2 Association of ACE2 and TMPRSS2 with COVID-19 clinical and 
laboratory outcomes 
 In our study, most of the subjects were asymptomatic. Yet, few symptomatic 
subjects were involved to be able to compare the expression of these protein among 
symptomatic cases. There was no significant difference and no association between 
the expression of ACE2 and TMPRSS2 among COVID-19 negative versus 
COVID-19 positive asymptomatic versus COVID-19 positive symptomatic cases 
in the overall population, and specifically among the pediatric population (Figure 
11 & Table 8). To our knowledge there is no direct report in the literature correlating 
the role of nasopharyngeal transmembrane ACE2 and TMPRSS2 expression with 
COVID-19 clinical presentations. However, in a meta-analysis that was conducted 
recently, there was no direct association between the prevalence of ACE (I/D) 
genotype and COVID-19 clinical outcome, but they reported that this allele was 
associated with an increased recovery rate [122]. It is necessary to understand the 
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relationship between these receptors and disease outcome for better disease 
management. Similarly, there was no significant association between the expression 
of ACE2 and TMPRSS2 with abnormal laboratory findings. Yet, various studies 
have reported that worse COVID-19 outcome could be associated with increased 
expression of TMPRSS2 and ACE2 [123-125]. Also, since most of the symptomatic 
cases have been reported so far are among adults, higher expression of ACE2 and 
TMPRSS2 could be one of the reasons for more severe infections in adults 
compared to children. However, our study remains inconclusive on this point 
because of low number of symptomatic subjects in our cohort but these findings 
could be significant if additional symptomatic families were involved in the study. 
 
CONCLUSION  
 In conclusion, COVID-19 pandemic is differentially affecting a vast number 
of people worldwide and an urgent understanding of the disease pathogenesis, and 
identifying disease associated host factors and biomarkers is essential for better 
disease management. Our results support the earlier described hypothesis that 
children have lesser expression of nasopharyngeal ACE2 and TMPRSS2 proteins, 
which could contribute to their protection against COVID-19, even when exposed 
to a COVID-19 positive individual. Furthermore, our study provides indications for 
future studies with larger sample numbers to further understand the theory behind 
the differential incidence of SARS-CoV-2. These findings could further help in 
specifically identifying patients who are likely to benefit more from specific types 
of therapies. Additionally, the differential expression of viral entry factors could 
have prognostic implications in COVID-19.  
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LIMITATION AND FUTURE STUDY  
 There are several limitations in this study. The COVID-19 positive subjects 
included in the current study were mostly asymptomatic, where a stronger age-
related association of nasopharyngeal expression of ACE2 and TMPRSS2 with 
SARS-CoV-2 infection status might be found if this study included more 
symptomatic family clusters. These results may become statistically significant 
with a larger sample size. Therefore, for future studies, conducting the analysis 
among larger number of subjects and including more symptomatic subjects would 


















Chapter 6: References  
1. Lu, H., C.W. Stratton, and Y.-W. Tang, Outbreak of pneumonia of unknown 
etiology in Wuhan, China: The mystery and the miracle. Journal of medical 
virology, 2020. 92(4): p. 401-402. 
2. Sohrabi, C., et al., World Health Organization declares global emergency: 
A review of the 2019 novel coronavirus (COVID-19). International Journal 
of Surgery, 2020. 76: p. 71-76. 
3. COVID-19 CORONAVIRUS PANDEMIC. 2020  [cited 2020 September 18, 
2020]; Available from: 
https://www.worldometers.info/coronavirus/#countries. 
4. Oran, D.P. and E.J. Topol, Prevalence of Asymptomatic SARS-CoV-2 
Infection : A Narrative Review. Ann Intern Med, 2020. 173(5): p. 362-367. 
5. Huang, C., et al., Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. Lancet, 2020. 395(10223): p. 497-506. 
6. Agyeman, A.A., et al., Smell and Taste Dysfunction in Patients With 
COVID-19: A Systematic Review and Meta-analysis. Mayo Clinic 
proceedings, 2020. 95(8): p. 1621-1631. 
7. Satarker, S. and M. Nampoothiri, Structural Proteins in Severe Acute 
Respiratory Syndrome Coronavirus-2. Archives of medical research, 2020. 
51(6): p. 482-491. 
8. Li, W., et al., Angiotensin-converting enzyme 2 is a functional receptor for 
the SARS coronavirus. Nature, 2003. 426(6965): p. 450-454. 
9. Zhou, P., et al., A pneumonia outbreak associated with a new coronavirus 
of probable bat origin. Nature, 2020. 579(7798): p. 270-273. 
10. Bertram, S., et al., Influenza and SARS-coronavirus activating proteases 
TMPRSS2 and HAT are expressed at multiple sites in human respiratory 
and gastrointestinal tracts. PloS one, 2012. 7(4): p. e35876-e35876. 
11. Hoffmann, M., et al., SARS-CoV-2 Cell Entry Depends on ACE2 and 
TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 
2020. 181(2): p. 271-280.e8. 
12. Liu, K., et al., Clinical features of COVID-19 in elderly patients: A 
comparison with young and middle-aged patients. The Journal of infection, 
2020. 80(6): p. e14-e18. 
13. Bunyavanich, S., A. Do, and A. Vicencio, Nasal Gene Expression of 
Angiotensin-Converting Enzyme 2 in Children and Adults. JAMA, 2020. 
323(23): p. 2427-2429. 
14. Matsuyama, S., et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-
expressing cells. Proc Natl Acad Sci U S A, 2020. 117(13): p. 7001-7003. 
15. Saheb Sharif-Askari, N., et al., Airways Expression of SARS-CoV-2 
Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and 
Increases with Smoking and COPD. Mol Ther Methods Clin Dev, 2020. 18: 
p. 1-6. 
16. Ksiazek, T.G., et al., A novel coronavirus associated with severe acute 
respiratory syndrome. N Engl J Med, 2003. 348(20): p. 1953-66. 
17. WHO, W.H.O. WHO Coronavirus Disease (COVID-19) Dashboard. 2020  
[cited 2020 09 October]. 
  
63 
18. Ministry of Public Health in Qatar, M. COVID-19 status in Qatar. 2020  
[cited 2020 09 October]. 
19. Wu, Z. and J.M. McGoogan, Characteristics of and Important Lessons 
From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: 
Summary of a Report of 72 314 Cases From the Chinese Center for Disease 
Control and Prevention. JAMA, 2020. 323(13): p. 1239-1242. 
20. Korean Society of Infectious, D., et al., Report on the Epidemiological 
Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the 
Republic of Korea from January 19 to March 2, 2020. Journal of Korean 
medical science, 2020. 35(10): p. e112-e112. 
21. Huang, C., et al., Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. Lancet (London, England), 2020. 
395(10223): p. 497-506. 
22. Shi, H., et al., Radiological findings from 81 patients with COVID-19 
pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious 
Diseases, 2020. 20(4): p. 425-434. 
23. Tabata, S., et al., Clinical characteristics of COVID-19 in 104 people with 
SARS-CoV-2 infection on the <em>Diamond Princess</em> cruise ship: a 
retrospective analysis. The Lancet Infectious Diseases, 2020. 20(9): p. 
1043-1050. 
24. Zhang, Z.-L., et al., Laboratory findings of COVID-19: a systematic review 
and meta-analysis. Scandinavian journal of clinical and laboratory 
investigation, 2020. 80(6): p. 441-447. 
25. Singh, A.K., et al., Diabetes in COVID-19: Prevalence, pathophysiology, 
prognosis and practical considerations. Diabetes & metabolic syndrome, 
2020. 14(4): p. 303-310. 
26. Zhao, Q., et al., The impact of COPD and smoking history on the severity of 
COVID-19: A systemic review and meta-analysis. Journal of medical 
virology, 2020: p. 10.1002/jmv.25889. 
27. Simonnet, A., et al., High Prevalence of Obesity in Severe Acute Respiratory 
Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical 
Ventilation. Obesity (Silver Spring, Md.), 2020. 28(7): p. 1195-1199. 
28. Guan, W.-J., et al., Clinical Characteristics of Coronavirus Disease 2019 in 
China. The New England journal of medicine, 2020. 382(18): p. 1708-1720. 
29. Lu, X., et al., SARS-CoV-2 Infection in Children. The New England journal 
of medicine, 2020. 382(17): p. 1663-1665. 
30. Dong, Y., et al., Epidemiology of COVID-19 Among Children in China. 
Pediatrics, 2020. 145(6). 
31. Wang, Z., et al., Clinical characteristics of children with COVID-19: a 
rapid review and meta-analysis. Annals of translational medicine, 2020. 
8(10): p. 620-620. 
32. Mantovani, A., et al., Coronavirus disease 2019 (COVID-19) in children 
and/or adolescents: a meta-analysis. Pediatric Research, 2020. 
33. Li, F., Structure, Function, and Evolution of Coronavirus Spike Proteins. 
Annual review of virology, 2016. 3(1): p. 237-261. 
34. Phan, T., Novel coronavirus: From discovery to clinical diagnostics. 
Infection, genetics and evolution : journal of molecular epidemiology and 
  
64 
evolutionary genetics in infectious diseases, 2020. 79: p. 104211-104211. 
35. Bakkers, M.J.G., et al., Betacoronavirus Adaptation to Humans Involved 
Progressive Loss of Hemagglutinin-Esterase Lectin Activity. Cell host & 
microbe, 2017. 21(3): p. 356-366. 
36. Fehr, A.R. and S. Perlman, Coronaviruses: an overview of their replication 
and pathogenesis. Methods in molecular biology (Clifton, N.J.), 2015. 
1282: p. 1-23. 
37. Huang, Q., et al., Structure of the N-terminal RNA-binding domain of the 
SARS CoV nucleocapsid protein. Biochemistry, 2004. 43(20): p. 6059-63. 
38. Ye, Y. and B.G. Hogue, Role of the coronavirus E viroporin protein 
transmembrane domain in virus assembly. Journal of virology, 2007. 81(7): 
p. 3597-3607. 
39. Astuti, I. and Ysrafil, Severe Acute Respiratory Syndrome Coronavirus 2 
(SARS-CoV-2): An overview of viral structure and host response. Diabetes 
& metabolic syndrome, 2020. 14(4): p. 407-412. 
40. Wong, A.C.P., et al., Global Epidemiology of Bat Coronaviruses. Viruses, 
2019. 11(2): p. 174. 
41. Liu, Y., et al., Aerodynamic analysis of SARS-CoV-2 in two Wuhan 
hospitals. Nature, 2020. 582(7813): p. 557-560. 
42. van Doremalen, N., et al., Aerosol and Surface Stability of SARS-CoV-2 as 
Compared with SARS-CoV-1, in N Engl J Med. 2020. p. 1564-1567. 
43. Hussain, A., et al., Novel COVID-19: A Comprehensive Review of 
Transmission, Manifestation, and Pathogenesis. Cureus, 2020. 12(5): p. 
e8184-e8184. 
44. Gengler, I., et al., Sinonasal pathophysiology of SARS-CoV-2 and COVID-
19: A systematic review of the current evidence. Laryngoscope Investig 
Otolaryngol, 2020. 5(3): p. 354-359. 
45. Crackower, M.A., et al., Angiotensin-converting enzyme 2 is an essential 
regulator of heart function. Nature, 2002. 417(6891): p. 822-8. 
46. Donoghue, M., et al., A novel angiotensin-converting enzyme-related 
carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ 
Res, 2000. 87(5): p. E1-9. 
47. Tipnis, S.R., et al., A human homolog of angiotensin-converting enzyme. 
Cloning and functional expression as a captopril-insensitive 
carboxypeptidase. J Biol Chem, 2000. 275(43): p. 33238-43. 
48. Keidar, S., M. Kaplan, and A. Gamliel-Lazarovich, ACE2 of the heart: 
From angiotensin I to angiotensin (1-7). Cardiovasc Res, 2007. 73(3): p. 
463-9. 
49. Santos, R.A.S., et al., The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-
Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev, 2018. 98(1): 
p. 505-553. 
50. Camargo, S.M., et al., Tissue-specific amino acid transporter partners 
ACE2 and collectrin differentially interact with hartnup mutations. 
Gastroenterology, 2009. 136(3): p. 872-82. 
51. Zou, X., et al., Single-cell RNA-seq data analysis on the receptor ACE2 
expression reveals the potential risk of different human organs vulnerable 
to 2019-nCoV infection. Front Med, 2020. 14(2): p. 185-192. 
  
65 
52. Walls, A.C., et al., Structure, Function, and Antigenicity of the SARS-CoV-
2 Spike Glycoprotein. Cell, 2020. 181(2): p. 281-292.e6. 
53. Yang, X.H., et al., Mice transgenic for human angiotensin-converting 
enzyme 2 provide a model for SARS coronavirus infection. Comp Med, 
2007. 57(5): p. 450-9. 
54. Zhang, H., et al., Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-
2 receptor: molecular mechanisms and potential therapeutic target. 
Intensive care medicine, 2020. 46(4): p. 586-590. 
55. Kuba, K., Y. Imai, and J.M. Penninger, Multiple functions of angiotensin-
converting enzyme 2 and its relevance in cardiovascular diseases. Circ J, 
2013. 77(2): p. 301-8. 
56. Bernstein, K.E., et al., Angiotensin-converting enzyme in innate and 
adaptive immunity. Nature reviews. Nephrology, 2018. 14(5): p. 325-336. 
57. Santos, R.A.S., et al., The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-
Angiotensin System: Focus on Angiotensin-(1-7). Physiological reviews, 
2018. 98(1): p. 505-553. 
58. Jia, H.P., et al., ACE2 receptor expression and severe acute respiratory 
syndrome coronavirus infection depend on differentiation of human airway 
epithelia. Journal of virology, 2005. 79(23): p. 14614-14621. 
59. Patel, V.B., et al., Angiotensin II induced proteolytic cleavage of myocardial 
ACE2 is mediated by TACE/ADAM-17: A positive feedback mechanism in 
the RAS. Journal of Molecular and Cellular Cardiology, 2014. 66: p. 167-
176. 
60. Swärd, P., et al., Age and sex differences in soluble ACE2 may give insights 
for COVID-19. Critical care (London, England), 2020. 24(1): p. 221-221. 
61. Leow, M.K.S., Clarifying the controversial risk-benefit profile of soluble 
ACE2 in COVID-19. Critical Care, 2020. 24(1): p. 396. 
62. Kuba, K., et al., A crucial role of angiotensin converting enzyme 2 (ACE2) 
in SARS coronavirus-induced lung injury. Nat Med, 2005. 11(8): p. 875-9. 
63. Oudit, G.Y., et al., SARS‐coronavirus modulation of myocardial ACE2 
expression and inflammation in patients with SARS. European journal of 
clinical investigation, 2009. 39(7): p. 618-625. 
64. Ni, W., et al., Acute Myocardial Injury at Hospital Admission Is Associated 
With All-Cause Mortality in COVID-19. Journal of the American College of 
Cardiology, 2020. 76(1): p. 124-125. 
65. Ye, M., et al., Glomerular localization and expression of Angiotensin-
converting enzyme 2 and Angiotensin-converting enzyme: implications for 
albuminuria in diabetes. J Am Soc Nephrol, 2006. 17(11): p. 3067-75. 
66. Hirsch, J.S., et al., Kidney International, 2020. 98(1): p. 209-218. 
67. Pal, R. and M. Banerjee, COVID-19 and the endocrine system: exploring 
the unexplored. Journal of Endocrinological Investigation, 2020. 43(7): p. 
1027-1031. 
68. Hadi, A., et al., Coronavirus Disease-19 (COVID-19) associated with 
severe acute pancreatitis: Case report on three family members. 
Pancreatology, 2020. 20(4): p. 665-667. 
69. Mao, L., et al., Neurologic Manifestations of Hospitalized Patients With 
Coronavirus Disease 2019 in Wuhan, China. JAMA Neurology, 2020. 
  
66 
77(6): p. 683-690. 
70. Chen, N., et al., Epidemiological and clinical characteristics of 99 cases of 
2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. 
Lancet, 2020. 395(10223): p. 507-513. 
71. Lucas, J.M., et al., The androgen-regulated type II serine protease 
TMPRSS2 is differentially expressed and mislocalized in prostate 
adenocarcinoma. J Pathol, 2008. 215(2): p. 118-25. 
72. Kesic, M.J., et al., Exposure to ozone modulates human airway 
protease/antiprotease balance contributing to increased influenza A 
infection. PloS one, 2012. 7(4): p. e35108-e35108. 
73. Li, W., et al., Angiotensin-converting enzyme 2 is a functional receptor for 
the SARS coronavirus. Nature, 2003. 426(6965): p. 450-4. 
74. Li, F., et al., Structure of SARS coronavirus spike receptor-binding domain 
complexed with receptor. Science, 2005. 309(5742): p. 1864-8. 
75. Chen, Y., Q. Liu, and D. Guo, Emerging coronaviruses: Genome structure, 
replication, and pathogenesis. Journal of medical virology, 2020. 92(4): p. 
418-423. 
76. Le Bon, A. and D.F. Tough, Links between innate and adaptive immunity 
via type I interferon. Curr Opin Immunol, 2002. 14(4): p. 432-6. 
77. Hertzog, P.J., L.A. O'Neill, and J.A. Hamilton, The interferon in TLR 
signaling: more than just antiviral. Trends Immunol, 2003. 24(10): p. 534-
9. 
78. Zhao, J., J. Zhao, and S. Perlman, T cell responses are required for 
protection from clinical disease and for virus clearance in severe acute 
respiratory syndrome coronavirus-infected mice. Journal of virology, 2010. 
84(18): p. 9318-9325. 
79. Liu, J., et al., Novel immunodominant peptide presentation strategy: a 
featured HLA-A*2402-restricted cytotoxic T-lymphocyte epitope stabilized 
by intrachain hydrogen bonds from severe acute respiratory syndrome 
coronavirus nucleocapsid protein. J Virol, 2010. 84(22): p. 11849-57. 
80. Qin, C., et al., Dysregulation of Immune Response in Patients With 
Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of 
America, 2020. 71(15): p. 762-768. 
81. Zhou, Y., et al., Pathogenic T-cells and inflammatory monocytes incite 
inflammatory storms in severe COVID-19 patients. National Science 
Review, 2020. 
82. Xu, Z., et al., Pathological findings of COVID-19 associated with acute 
respiratory distress syndrome. The Lancet. Respiratory medicine, 2020. 
8(4): p. 420-422. 
83. Giamarellos-Bourboulis, E.J., et al., Complex Immune Dysregulation in 
COVID-19 Patients with Severe Respiratory Failure. Cell host & microbe, 
2020. 27(6): p. 992-1000.e3. 
84. Grifoni, A., et al., Targets of T Cell Responses to SARS-CoV-2 Coronavirus 
in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 2020. 
181(7): p. 1489-1501.e15. 
85. To, K.K., et al., Temporal profiles of viral load in posterior oropharyngeal 
  
67 
saliva samples and serum antibody responses during infection by SARS-
CoV-2: an observational cohort study. Lancet Infect Dis, 2020. 20(5): p. 
565-574. 
86. Guo, L., et al., Profiling Early Humoral Response to Diagnose Novel 
Coronavirus Disease (COVID-19). Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America, 2020. 71(15): p. 
778-785. 
87. Yuki, K., M. Fujiogi, and S. Koutsogiannaki, COVID-19 pathophysiology: 
A review. Clinical immunology (Orlando, Fla.), 2020. 215: p. 108427-
108427. 
88. Saule, P., et al., Accumulation of memory T cells from childhood to old age: 
central and effector memory cells in CD4(+) versus effector memory and 
terminally differentiated memory cells in CD8(+) compartment. Mech 
Ageing Dev, 2006. 127(3): p. 274-81. 
89. Li, M., et al., Age related human T cell subset evolution and senescence. 
Immunity & ageing : I & A, 2019. 16: p. 24-24. 
90. Connors, T.J., et al., Airway CD8(+) T Cells Are Associated with Lung 
Injury during Infant Viral Respiratory Tract Infection. American journal of 
respiratory cell and molecular biology, 2016. 54(6): p. 822-830. 
91. Thome, J.J.C., et al., Early-life compartmentalization of human T cell 
differentiation and regulatory function in mucosal and lymphoid tissues. 
Nature Medicine, 2016. 22(1): p. 72-77. 
92. Nickbakhsh, S., et al., Virus-virus interactions impact the population 
dynamics of influenza and the common cold. Proceedings of the National 
Academy of Sciences of the United States of America, 2019. 116(52): p. 
27142-27150. 
93. Chen, J., et al., Individual variation of the SARS-CoV-2 receptor ACE2 gene 
expression and regulation. Aging cell, 2020. 19(7): p. e13168. 
94. McIntosh, K., M.S. Hirsch, and A. Bloom, Coronavirus disease 2019 
(COVID-19). UpToDate Hirsch MS Bloom, 2020. 5. 
95. Peng, L., et al., SARS-CoV-2 can be detected in urine, blood, anal swabs, 
and oropharyngeal swabs specimens. Journal of medical virology, 2020: p. 
10.1002/jmv.25936. 
96. Sethuraman, N., S.S. Jeremiah, and A. Ryo, Interpreting Diagnostic Tests 
for SARS-CoV-2. Jama, 2020. 323(22): p. 2249-2251. 
97. Tang, Y.-W., et al., Laboratory Diagnosis of COVID-19: Current Issues and 
Challenges. Journal of clinical microbiology, 2020. 58(6): p. e00512-20. 
98. Mathuria, J.P., R. Yadav, and Rajkumar, Laboratory diagnosis of SARS-
CoV-2 - A review of current methods. Journal of infection and public health, 
2020. 13(7): p. 901-905. 
99. Guan, W.-j., et al., Clinical characteristics of 2019 novel coronavirus 
infection in China. MedRxiv, 2020. 
100. Zhang, D.-H., et al., In silico screening of Chinese herbal medicines with 
the potential to directly inhibit 2019 novel coronavirus. Journal of 
integrative medicine, 2020. 18(2): p. 152-158. 
101. Wang, M., et al., Remdesivir and chloroquine effectively inhibit the recently 
emerged novel coronavirus (2019-nCoV) in vitro. Cell research, 2020. 
  
68 
30(3): p. 269-271. 
102. Yao, X., et al., In Vitro Antiviral Activity and Projection of Optimized 
Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute 
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious 
diseases : an official publication of the Infectious Diseases Society of 
America, 2020. 71(15): p. 732-739. 
103. Gao, J., Z. Tian, and X. Yang, Breakthrough: Chloroquine phosphate has 
shown apparent efficacy in treatment of COVID-19 associated pneumonia 
in clinical studies. Biosci Trends, 2020. 14(1): p. 72-73. 
104. Holshue, M.L., et al., First Case of 2019 Novel Coronavirus in the United 
States. The New England journal of medicine, 2020. 382(10): p. 929-936. 
105. Furuta, Y., et al., Mechanism of action of T-705 against influenza virus. 
Antimicrobial agents and chemotherapy, 2005. 49(3): p. 981-986. 
106. Chen, C., et al., Favipiravir versus arbidol for COVID-19: a randomized 
clinical trial. MedRxiv, 2020. 
107. Yeh, K.-M., et al., Experience of using convalescent plasma for severe acute 
respiratory syndrome among healthcare workers in a Taiwan hospital. The 
Journal of antimicrobial chemotherapy, 2005. 56(5): p. 919-922. 
108. Shen, C., et al., Treatment of 5 Critically Ill Patients With COVID-19 With 
Convalescent Plasma. JAMA, 2020. 323(16): p. 1582-1589. 
109. Mohapatra, P.R., B. Mishra, and B. Behera, BCG vaccination induced 
protection from COVID-19. The Indian Journal of Tuberculosis, 2020. 
110. Kaur, S.P. and V. Gupta, COVID-19 Vaccine: A comprehensive status 
report. Virus Research, 2020: p. 198114. 
111. Chibber, P., et al., Advances in the possible treatment of COVID-19: A 
review. European journal of pharmacology, 2020. 883: p. 173372-173372. 
112. Ball, P., The lightning-fast quest for COVID vaccines - and what it means 
for other diseases, in Nature. 2020: England. 
113. Meo, S.A., et al., COVID-19 vaccines: comparison of biological, 
pharmacological characteristics and adverse effects of Pfizer/BioNTech 
and Moderna Vaccines. Eur Rev Med Pharmacol Sci, 2021. 25(3): p. 1663-
1669. 
114. Folegatti, P.M., et al., Safety and immunogenicity of the ChAdOx1 nCoV-19 
vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-
blind, randomised controlled trial. The Lancet, 2020. 396(10249): p. 467-
478. 
115. Abd El-Aziz, T.M., A. Al-Sabi, and J.D. Stockand, Human recombinant 
soluble ACE2 (hrsACE2) shows promise for treating severe COVID-19. 
Signal Transduction and Targeted Therapy, 2020. 5(1): p. 258. 
116. Zoufaly, A., et al., Human recombinant soluble ACE2 in severe COVID-19. 
The Lancet Respiratory Medicine, 2020. 8(11): p. 1154-1158. 
117. Saheb Sharif-Askari, N., et al., Airways Expression of SARS-CoV-2 
Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and 
Increases with Smoking and COPD. Molecular Therapy - Methods & 
Clinical Development, 2020. 18: p. 1-6. 
118. Matsuyama, S., et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-
expressing cells. Proceedings of the National Academy of Sciences of the 
  
69 
United States of America, 2020. 117(13): p. 7001-7003. 
119. Brodin, P., Why is COVID-19 so mild in children? Acta Paediatrica, 2020. 
109(6): p. 1082-1083. 
120. Nikiforuk, A.M., et al., The Contrasting Role of Nasopharyngeal 
Angiotensin Converting Enzyme 2 (<em>ACE2</em>) Expression in 
SARS-CoV-2 Infection: A Cross-Sectional Study of People Tested for 
COVID-19 in British Columbia. medRxiv, 2020: p. 2020.11.23.20237206. 
121. Barker, H. and S. Parkkila, Bioinformatic characterization of angiotensin-
converting enzyme 2, the entry receptor for SARS-CoV-2. PLOS ONE, 2020. 
15(10): p. e0240647. 
122. Hatami, N., et al., Worldwide ACE (I/D) polymorphism may affect COVID-
19 recovery rate: an ecological meta-regression. Endocrine, 2020. 68(3): p. 
479-484. 
123. Asselta, R., et al., ACE2 and TMPRSS2 variants and expression as 
candidates to sex and country differences in COVID-19 severity in Italy. 
Aging (Albany NY), 2020. 12(11): p. 10087-10098. 
124. Bunyavanich, S., C. Grant, and A. Vicencio, Racial/Ethnic Variation in 
Nasal Gene Expression of Transmembrane Serine Protease 2 (TMPRSS2). 
JAMA, 2020. 324(15): p. 1567-1568. 
125. Russo, R., et al., Genetic Analysis of the Coronavirus SARS-CoV-2 Host 
Protease TMPRSS2 in Different Populations. Frontiers in genetics, 2020. 
















Chapter 7: Appendix  









7.2 Appendix B: QU IRB approval 
 
 
